

Theravance Biopharma, Inc.
 Form 4
 May 22, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Mammen Mathai

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA
 US, INC., 901 GATEWAY BLVD.

(Street)

SOUTH SAN
 FRANCISCO, CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

Theravance Biopharma, Inc. [TBPH]

3. Date of Earliest Transaction
 (Month/Day/Year)

05/20/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___ 10% Owner
 ___X___ Officer (give title below) ___ Other (specify below)

SVP, Research & Development

6. Individual or Joint/Group Filing(Check Applicable Line)

___X___ Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				Code V Amount (D) Price			
Ordinary Shares	05/20/2015		F	673 D \$ 14.24	227,183	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Theravance Biopharma, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares
						Code	V	(A)	(D)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Mammen Mathai C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BLVD. SOUTH SAN FRANCISCO, CA 94080			SVP, Research & Development	

Signatures

Brett A. Grimaud as
Attorney-in-Fact
Date: 05/22/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. "font-family:Arial;font-size:10pt;">

PART I
FINANCIAL INFORMATION
Page-3

ITEM 1.
Financial Statements
Page-3

Consolidated Statements of Condition

Page-3

Consolidated Statements of Comprehensive Income

Page-4

Consolidated Statements of Changes in Stockholders' Equity

Page-5

Consolidated Statements of Cash Flows

Page-6

Notes to Consolidated Financial Statements

Page-7

ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Page-30

ITEM 3.

Quantitative and Qualitative Disclosure about Market Risk

Page-44

ITEM 4.

Controls and Procedures

Page-44

PART II

OTHER INFORMATION

Page-45

ITEM 1.

Legal Proceedings

Page-45

ITEM 1A.

Risk Factors

Page-45

Explanation of Responses:

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds

Page-45

ITEM 3.

Defaults Upon Senior Securities

Page-45

ITEM 4.

Mine Safety Disclosures

Page-45

ITEM 5.

Other Information

Page-45

ITEM 6.

Exhibits

Page-46

SIGNATURES

Page-48

Page-2

PART I FINANCIAL INFORMATION

ITEM 1. Financial Statements

BANK OF MARIN BANCORP
CONSOLIDATED STATEMENTS OF CONDITION
at September 30, 2016 and December 31, 2015

(in thousands, except share data; unaudited)	September 30, 2016	December 31, 2015
Assets		
Cash and due from banks	\$ 96,930	\$ 26,343
Investment securities		
Held-to-maturity, at amortized cost	46,423	69,637
Available-for-sale, at fair value	378,996	417,787
Total investment securities	425,419	487,424
Loans, net of allowance for loan losses of \$15,713 and \$14,999 at September 30, 2016 and December 31, 2015, respectively	1,451,950	1,436,229
Bank premises and equipment, net	8,611	9,305
Goodwill	6,436	6,436
Core deposit intangible	2,713	3,113
Interest receivable and other assets	62,762	62,284
Total assets	\$ 2,054,821	\$ 2,031,134
Liabilities and Stockholders' Equity		
Liabilities		
Deposits		
Non-interest bearing	\$ 860,638	\$ 770,087
Interest bearing		
Transaction accounts	91,979	114,277
Savings accounts	156,225	141,316
Money market accounts	533,682	541,089
Time accounts	158,945	161,457
Total deposits	1,801,469	1,728,226
Federal Home Loan Bank ("FHLB") and other borrowings	—	67,000
Subordinated debentures	5,540	5,395
Interest payable and other liabilities	16,032	16,040
Total liabilities	1,823,041	1,816,661
Stockholders' Equity		
Preferred stock, no par value, Authorized - 5,000,000 shares, none issued	—	—
Common stock, no par value, Authorized - 15,000,000 shares; Issued and outstanding - 6,123,181 and 6,068,543 at September 30, 2016 and December 31, 2015, respectively	86,926	84,727
Retained earnings	142,427	129,553
Accumulated other comprehensive income, net	2,427	193
Total stockholders' equity	231,780	214,473
Total liabilities and stockholders' equity	\$ 2,054,821	\$ 2,031,134

Explanation of Responses:

The accompanying notes are an integral part of these consolidated financial statements (unaudited).

Page-3

BANK OF MARIN BANCORP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands, except per share amounts; unaudited)	Three months ended		Nine months ended	
	September 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015
Interest income				
Interest and fees on loans	\$17,840	\$ 15,498	\$51,078	\$46,164
Interest on investment securities				
Securities of U.S. government agencies	1,283	1,223	3,826	3,248
Obligations of state and political subdivisions	569	527	1,743	1,578
Corporate debt securities and other	38	162	220	546
Interest on Federal funds sold and short-term investments	104	35	155	107
Total interest income	19,834	17,445	57,022	51,643
Interest expense				
Interest on interest-bearing transaction accounts	27	28	82	88
Interest on savings accounts	15	12	43	37
Interest on money market accounts	112	125	330	375
Interest on time accounts	190	212	579	649
Interest on FHLB and other borrowings	—	80	478	236
Interest on subordinated debentures	109	105	325	314
Total interest expense	453	562	1,837	1,699
Net interest income	19,381	16,883	55,185	49,944
(Reversal of) provision for loan losses	(1,550)	—	(1,550)	—
Net interest income after provision for loan losses	20,931	16,883	56,735	49,944
Non-interest income				
Service charges on deposit accounts	447	489	1,344	1,518
Wealth Management and Trust Services	506	568	1,599	1,809
Debit card interchange fees	393	372	1,112	1,087
Merchant interchange fees	114	171	355	430
Earnings on bank-owned life insurance	216	204	626	610
Dividends on FHLB stock	223	209	577	817
Gains on investment securities, net	—	72	394	80
Other income	215	213	691	744
Total non-interest income	2,114	2,298	6,698	7,095
Non-interest expense				
Salaries and related benefits	6,683	6,300	20,155	19,762
Occupancy and equipment	1,275	1,346	3,731	4,181
Depreciation and amortization	449	441	1,343	1,512
Federal Deposit Insurance Corporation insurance	253	250	760	739
Data processing	894	835	2,666	2,413
Professional services	476	493	1,528	1,572
Directors' expense	143	182	448	620
Information technology	307	186	665	554
Provision for losses on off-balance sheet commitments	—	324	150	14
Other expense	1,430	1,281	4,491	4,447
Total non-interest expense	11,910	11,638	35,937	35,814
Income before provision for income taxes	11,135	7,543	27,496	21,225
Provision for income taxes	4,171	2,770	10,049	7,709
Net income	\$6,964	\$ 4,773	\$17,447	\$13,516

Explanation of Responses:

Edgar Filing: Theravance Biopharma, Inc. - Form 4

Net income per common share:				
Basic	\$1.14	\$ 0.80	\$2.87	\$2.27
Diluted	\$1.14	\$ 0.79	\$2.86	\$2.23
Weighted average shares:				
Basic	6,083	5,963	6,070	5,943
Diluted	6,117	6,067	6,106	6,059
Dividends declared per common share	\$0.25	\$ 0.22	\$0.75	\$0.66
Comprehensive income:				
Net income	\$6,964	\$ 4,773	\$17,447	\$13,516
Other comprehensive income				
Change in net unrealized (loss) gain on available-for-sale securities	(831)1,523	4,211	1,037
Reclassification adjustment for gains on available-for-sale securities included in net income	—	—	(394)(8)
Net change in unrealized (loss) gain on available-for-sale securities, before tax	(831)1,523	3,817	1,029
Deferred tax (benefit) expense	(367)654	1,583	517
Other comprehensive (loss) income, net of tax	(464)869	2,234	512
Comprehensive income	\$6,500	\$ 5,642	\$19,681	\$14,028

The accompanying notes are an integral part of these consolidated financial statements (unaudited).

Page-4

BANK OF MARIN BANCORP

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

for the year ended December 31, 2015 and the nine months ended September 30, 2016

(in thousands, except share data; unaudited)	Common Stock		Retained Earnings	Accumulated Other Comprehensive Income (Loss), Net of Taxes	Total
	Shares	Amount			
Balance at December 31, 2014	5,939,482	\$82,436	\$116,502	\$ 1,088	\$200,026
Net income	—	—	18,441	—	18,441
Other comprehensive loss	—	—	—	(895)	(895)
Stock options exercised	37,071	1,139	—	—	1,139
Excess tax benefit - stock-based compensation	—	212	—	—	212
Stock issued under employee stock purchase plan	339	17	—	—	17
Restricted stock granted	15,970	—	—	—	—
Restricted stock forfeited / cancelled	(450)	—	—	—	—
Stock-based compensation - stock options	—	252	—	—	252
Stock-based compensation - restricted stock	—	384	—	—	384
Cash dividends paid on common stock	—	—	(5,390)	—	(5,390)
Stock purchased by directors under director stock plan	245	12	—	—	12
Stock issued in payment of director fees	5,295	275	—	—	275
Stock issued from exercise of warrants	70,591	—	—	—	—
Balance at December 31, 2015	6,068,543	\$84,727	\$129,553	\$ 193	\$214,473
Net income	—	—	17,447	—	17,447
Other comprehensive income	—	—	—	2,234	2,234
Stock options exercised	32,117	1,087	—	—	1,087
Excess tax benefit - stock-based compensation	—	119	—	—	119
Stock issued under employee stock purchase plan	488	23	—	—	23
Restricted stock granted	16,910	—	—	—	—
Stock-based compensation - stock options	—	266	—	—	266
Stock-based compensation - restricted stock	—	444	—	—	444
Cash dividends paid on common stock	—	—	(4,573)	—	(4,573)
Stock purchased by directors under director stock plan	516	26	—	—	26
Stock issued in payment of director fees	4,607	234	—	—	234
Balance at September 30, 2016	6,123,181	\$86,926	\$142,427	\$ 2,427	\$231,780

The accompanying notes are an integral part of these consolidated financial statements (unaudited).

BANK OF MARIN BANCORP
CONSOLIDATED STATEMENTS OF CASH FLOWS
for the nine months ended September 30, 2016 and 2015

(in thousands; unaudited)	September 30, 2016	September 30, 2015
Cash Flows from Operating Activities:		
Net income	\$ 17,447	\$ 13,516
Adjustments to reconcile net income to net cash provided by operating activities:		
(Reversal of) provision for loan losses	(1,550))
Provision for losses on off-balance sheet commitments	150	14
Compensation expense via common stock for director fees	146	207
Stock-based compensation expense	710	477
Excess tax benefits from exercised or vested stock-based awards	(119)) (150)
Amortization of core deposit intangible	400	464
Amortization of investment security premiums, net of accretion of discounts	2,293	2,038
Accretion of discount on acquired loans	(1,526)) (1,569)
Accretion of discount on subordinated debentures	145	158
Net amortization of deferred loan origination costs/fees	100	(374)
Write-down of other real estate owned	13	40
Gain on sale of investment securities	(394)) (80)
Depreciation and amortization	1,343	1,512
Loss on disposal of premises and equipment	3	4
Earnings on bank-owned life insurance policies	(626)) (610)
Net change in operating assets and liabilities:		
Interest receivable	998	303
Interest payable	(49)) (13)
Deferred rent and other rent-related expenses	(287)) 42
Other assets	1,364	1,930
Other liabilities	(246)) (819)
Total adjustments	2,868	3,574
Net cash provided by operating activities	20,315	17,090
Cash Flows from Investing Activities:		
Purchase of held-to-maturity securities	(2,424)) (2,375)
Purchase of available-for-sale securities	(138,432)) (189,755)
Proceeds from sale of available-for-sale securities	68,673	1,559
Proceeds from sale of held-to-maturity securities	—	1,015
Purchase of bank-owned life insurance policies	(2,133)) —
Proceeds from paydowns/maturity of held-to-maturity securities	25,150	30,529
Proceeds from paydowns/maturity of available-for-sale securities	110,978	54,966
Proceeds from the sale of loan	—	1,502
Loans originated and principal collected, net	(11,723)) 403
Purchase of FHLB stock	(1,792)) (136)
Purchase of premises and equipment	(652)) (1,194)
Cash paid for low income housing tax credit investment	(298)) (645)
Net cash provided by (used in) investing activities	47,347) (104,131)
Cash Flows from Financing Activities:		
Net increase in deposits	73,243	83,863
Proceeds from stock options exercised	1,087	888
Proceeds from stock issued under employee and director stock purchase plans	49	24

Explanation of Responses:

Edgar Filing: Theravance Biopharma, Inc. - Form 4

Repayment of Federal Home Loan Bank borrowings	(67,000) —	
Cash dividends paid on common stock	(4,573) (3,936)
Excess tax benefits from exercised or vested stock-based awards	119	150	
Net cash provided by financing activities	2,925	80,989	
Net increase (decrease) in cash and cash equivalents	70,587	(6,052)
Cash and cash equivalents at beginning of period	26,343	41,367	
Cash and cash equivalents at end of period	\$ 96,930	\$ 35,315	
Supplemental disclosure of cash flow information:			
Cash paid for interest	\$ 1,741	\$ 1,554	
Cash paid for income taxes	\$ 9,095	\$ 6,603	
Supplemental disclosure of non-cash investing and financing activities:			
Change in unrealized gain on available-for-sale securities	\$ 3,817	\$ (1,029)
Transfer of loan to loans held-for-sale at fair value	\$ —	\$ 1,502	
Subscription in low income housing tax credit investment	\$ —	\$ 1,023	
Stock issued in payment of director fees	\$ 234	\$ 275	

The accompanying notes are an integral part of these consolidated financial statements (unaudited).

Page-6

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

Note 1: Basis of Presentation

The consolidated financial statements include the accounts of Bank of Marin Bancorp (“Bancorp”), a bank holding company, and its wholly-owned bank subsidiary, Bank of Marin (the “Bank”), a California state-chartered commercial bank. References to “we,” “our,” “us” mean the holding company and the Bank that are consolidated for financial reporting purposes. The accompanying unaudited consolidated interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to those rules and regulations. Although we believe that the disclosures are adequate and the information presented is not misleading, we suggest that these interim financial statements be read in conjunction with the annual financial statements and the notes thereto included in our 2015 Annual Report on Form 10-K. In the opinion of Management, the unaudited consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the consolidated financial position, the results of operations, changes in comprehensive income, changes in stockholders’ equity, and cash flows for the periods presented. All material intercompany transactions have been eliminated. The results of these interim periods may not be indicative of the results for the full year or for any other period. We have evaluated subsequent events through the date of filing with the SEC and have determined that there are no subsequent events that require additional recognition or disclosure.

The NorCal Community Bancorp Trusts I and II, respectively (the “Trusts”) were formed for the sole purpose of issuing trust preferred securities. Bancorp is not considered the primary beneficiary of the Trusts (variable interest entities), therefore the Trusts are not consolidated in our consolidated financial statements, but rather the subordinated debentures are shown as a liability on our consolidated statements of condition (See Note 6, Borrowings). Bancorp's investment in the securities of the Trusts is accounted for under the equity method and is included in interest receivable and other assets on the consolidated statements of condition.

The following table shows: 1) weighted average basic shares, 2) potentially dilutive weighted average common shares related to stock options, unvested restricted stock awards and stock warrant, and 3) weighted average diluted shares. Basic earnings per share (“EPS”) are calculated by dividing net income by the weighted average number of common shares outstanding during each period, excluding unvested restricted stock awards. Diluted EPS are calculated using the weighted average number of potentially dilutive common shares, which is based on average market prices during the three months of the reporting period, under the treasury stock method. The number of potentially dilutive common shares included in year-to-date diluted EPS is a year-to-date weighted average of potentially dilutive common shares included in each quarterly diluted EPS computation. We have two forms of our outstanding common stock: common stock and unvested restricted stock awards. Holders of unvested restricted stock awards receive non-forfeitable dividends at the same rate as common shareholders and they both share equally in undistributed earnings. Therefore, under the two-class method, the difference in EPS is not significant for these participating securities.

(in thousands, except per share data)	Three months ended		Nine months ended	
	September 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015
Weighted average basic shares outstanding	6,083	5,963	6,070	5,943
Potentially dilutive common shares related to:				
Stock options	27	35	30	41
Unvested restricted stock awards	7	5	6	5
Warrant	—	64	—	70
Weighted average diluted shares outstanding	6,117	6,067	6,106	6,059
Net income	\$6,964	\$ 4,773	\$ 17,447	\$ 13,516

Explanation of Responses:

Edgar Filing: Theravance Biopharma, Inc. - Form 4

Basic EPS	\$1.14	\$ 0.80	\$2.87	\$ 2.27
Diluted EPS	\$1.14	\$ 0.79	\$2.86	\$ 2.23
Weighted average anti-dilutive shares not included in the calculation of diluted EPS	71	42	65	35

Page-7

Note 2: Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU is a converged standard involving FASB and International Financial Reporting Standards that provides a single comprehensive revenue recognition model for all contracts with customers across transactions and industries. The core principal of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount and at a time that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Subsequent updates related to Revenue from Contracts with Customers (Topic 606) are as follows:

August 2015 ASU No. 2015-14 - Deferral of the Effective Date, institutes a one-year deferral of the effective date of this amendment to annual reporting periods beginning after December 15, 2017. Early application is permitted only as of annual periods beginning after December 15, 2016, including interim reporting periods within that reporting period.

March 2016 ASU No. 2016-08 - Principal versus Agent Considerations (Reporting Revenue Gross versus Net), clarifies the implementation guidance on principal versus agent considerations and on the use of indicators that assist an entity in determining whether it controls a specified good or service before it is transferred to the customer.

April 2016 ASU No. 2016-10 - Identifying Performance Obligations and Licensing, provides guidance in determining performance obligations in a contract with a customer and clarifies whether a promise to grant a license provides a right to access or the right to use intellectual property.

May 2016 ASU No. 2016-12 - Narrow Scope Improvements and Practical Expedients, gives further guidance on assessing collectability, presentation of sales taxes, noncash consideration, and completed contracts and contract modifications at transition.

We are currently evaluating the provisions of these updates and will be monitoring developments and additional guidance to determine the potential impact the new standards will have on our financial condition and results of operations.

In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments in this ASU make improvements to GAAP related to financial instruments that include the following as applicable to us.

Equity investments, except for those accounted for under the equity method of accounting or those that result in consolidation of the investee, are required to be measured at fair value with changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

Simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment - if impairment exists, this requires measuring the investment at fair value.

Eliminates the requirement for public companies to disclose the method(s) and significant assumptions used to estimate the fair value that is currently required to be disclosed for financial instruments measured at amortized cost on the balance sheet.

Public companies will be required to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes.

Requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or the accompanying notes to the financial statements.

The reporting entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity's other deferred tax assets.

ASU 2016-01 is effective for public business entities for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. This ASU will impact our financial statement disclosures, however, we do not expect it to have a material impact on our financial condition or results of operations.

Page-8

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This ASU was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities, including leases classified as operating leases under previous GAAP, on the balance sheet and requiring additional disclosures of key information about leasing arrangements. This ASU applies to leasing arrangements exceeding a twelve month term. ASU 2016-02 is effective for annual periods, including interim periods within those annual periods beginning after December 15, 2018 and requires a modified retrospective method upon adoption. Early application of the amendments is permitted. We are currently evaluating the provisions of this ASU and will be monitoring developments and additional guidance to determine the timing of our adoption and the potential outcome the amendments will have on our financial condition and results of operations.

In March 2016, the FASB issued ASU No. 2016-05, Derivatives and Hedging (Topic 815): Effect of Derivative Contract Novations on Existing Hedge Accounting Relationships. A contract novation refers to replacing one of the parties to a derivative instrument with a new party. This ASU clarifies that a change in counterparty in a derivative instrument does not, in and of itself, require dedesignation of that hedging relationship and therefore discontinue the application of hedge accounting. ASU 2016-05 is effective for financial statements issued for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted in any interim or annual period. We do not expect this ASU to have a material impact on our financial condition or results of operations.

In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This ASU identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeiture accounting, and classifications on the statement of cash flows. ASU 2016-09 is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted in any interim or annual period. We are currently evaluating the the provisions of this ASU and will be monitoring developments and additional guidance to determine the potential outcome the amendments will have on our financial condition and results of operations.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This ASU replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses, requiring a financial asset measured at amortized cost basis to be presented at the net amount expected to be collected. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which is likely to result in more timely recognition of such losses. In addition, the accounting for purchased credit impaired financial assets will make the allowance for credit losses more comparable between originated assets and purchased financial assets, as well as reduce complexity with the accounting for interest income. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the provisions of this ASU and will be monitoring developments and additional guidance to determine the timing of our adoption and the potential outcome the amendments will have on our financial condition and results of operations.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. This ASU provides guidance on how to present and classify eight specific cash flow issues in the statement of cash flows. The ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The amendments should be applied using a retrospective transition method to each period presented, if practical. We do not expect this ASU to have a material impact on our financial condition or results of operations.

Note 3: Fair Value of Assets and Liabilities

Explanation of Responses:

Fair Value Hierarchy and Fair Value Measurement

We group our assets and liabilities that are measured at fair value into three levels within the fair value hierarchy, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. These levels are:

Level 1: Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities.

Page-9

Level 2: Valuations are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuations for which all significant assumptions are observable or can be corroborated by observable market data.

Level 3: Valuations are based on unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Values are determined using pricing models and discounted cash flow models and may include significant Management judgment and estimation.

Transfers between levels of the fair value hierarchy are recognized through our monthly and/or quarterly valuation process in the reporting period during which the event or circumstances that caused the transfer occurred.

The following table summarizes our assets and liabilities that were required to be recorded at fair value on a recurring basis.

(in thousands) Description of Financial Instruments	Carrying Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
September 30, 2016				
Securities available-for-sale:				
Mortgage-backed securities and collateralized mortgage obligations issued by U.S. government-sponsored agencies	\$252,824	\$	-\$252,199	\$ 625
Debentures of government-sponsored agencies	40,576	—	40,576	—
Privately-issued collateralized mortgage obligations	560	—	560	—
Obligations of state and political subdivisions	80,027	—	80,027	—
Corporate bonds	5,009	—	5,009	—
Derivative financial liabilities (interest rate contracts)	2,480	—	2,480	—
December 31, 2015				
Securities available-for-sale:				
Mortgage-backed securities and collateralized mortgage obligations issued by U.S. government-sponsored agencies	\$190,093	\$	-\$188,381	\$ 1,712
Debentures of government-sponsored agencies	160,892	—	160,892	—
Privately-issued collateralized mortgage obligations	4,150	—	4,150	—
Obligations of state and political subdivisions	57,673	—	57,673	—
Corporate bonds	4,979	—	4,979	—
Derivative financial assets (interest rate contracts)	3	—	3	—
Derivative financial liabilities (interest rate contracts)	1,658	—	1,658	—

Securities available-for-sale are recorded at fair value on a recurring basis. When available, quoted market prices (Level 1) are used to determine the fair value of securities available-for-sale. If quoted market prices are not available, we obtain pricing information from a reputable third-party service provider, who may utilize valuation techniques that use current market-based or independently sourced parameters, such as bid/ask prices, dealer-quoted prices, interest rates, benchmark yield curves, prepayment speeds, probability of default, loss severity and credit spreads (Level 2). Level 2 securities include obligations of state and political subdivisions, U.S. agencies or government-sponsored agencies' debt securities, mortgage-backed securities, government agency-issued and privately-issued collateralized

mortgage obligations. As of September 30, 2016 and December 31, 2015, there were no securities that were considered Level 1 securities. As of September 30, 2016, we had one available-for-sale security that was considered a Level 3 security. The security is a U.S. government agency obligation collateralized by a small number of business equipment loans guaranteed by the Small Business Administration ("SBA") program. This security is not actively traded and is owned only by a few investors. The significant unobservable data that is reflected in the fair value measurement include dealer quotes, projected prepayment speeds/average life and credit information, among other things. The decrease in fair value during 2016 was due to the pay-off of one of the larger loans in the pool collateralizing the security. The unrealized gain or loss on this SBA-guaranteed security decreased by \$15 thousand in the same period recorded as part of other comprehensive income.

Page-10

Securities held-to-maturity may be written down to fair value (determined using the same techniques discussed above for securities available-for-sale) as a result of an other-than-temporary impairment, if any.

On a recurring basis, derivative financial instruments are recorded at fair value, which is based on the income approach using observable Level 2 market inputs, reflecting market expectations of future interest rates as of the measurement date. Standard valuation techniques are used to calculate the present value of the future expected cash flows assuming an orderly transaction. Valuation adjustments may be made to reflect both our own credit risk and the counterparties' credit risk in determining the fair value of the derivatives. Level 2 inputs for the valuations are limited to observable market prices for London Interbank Offered Rate ("LIBOR") and Overnight Index Swap ("OIS") rates (for the very short term), quoted prices for LIBOR futures contracts, observable market prices for LIBOR and OIS swap rates, and one-month and three-month LIBOR basis spreads at commonly quoted intervals. Mid-market pricing of the inputs is used as a practical expedient in the fair value measurements. We project spot rates at reset days specified by each swap contract to determine future cash flows, then discount to present value using either LIBOR or OIS curves depending on whether the swap positions are fully collateralized as of the measurement date. When the value of any collateral placed with counterparties is less than the interest rate derivative liability, a credit valuation adjustment ("CVA") is applied to reflect the credit risk we pose to counterparties. We have used the spread between the Standard & Poor's BBB rated U.S. Bank Composite rate and LIBOR for the closest maturity term corresponding to the duration of the swaps to derive the CVA. A similar credit risk adjustment, correlated to the credit standing of the counterparty, is made when collateral posted by the counterparty does not fully cover their liability to Bank of Marin. For further discussion on our methodology in valuing our derivative financial instruments, refer to Note 9.

Certain financial assets may be measured at fair value on a non-recurring basis. These assets are subject to fair value adjustments that result from the application of the lower of cost or fair value accounting or write-downs of individual assets, such as impaired loans and other real estate owned ("OREO").

The following table presents the carrying value of assets and liabilities measured at fair value on a non-recurring basis and that were held in the consolidated statements of condition at each respective period end, by level within the fair value hierarchy as of September 30, 2016 and December 31, 2015.

(in thousands)	Carrying Value	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
September 30, 2016				
Impaired loans ¹	\$ 124	\$	-\$	-\$ 124
Other real estate owned	408	—	—	408
December 31, 2015				
Impaired loans	\$ —	\$	-\$	-\$ —
Other real estate owned	421	—	—	421

¹Represents collateral-dependent loan principal balances that had been generally written down to the values of the underlying collateral and reflected net of specific valuation allowances. At September 30, 2016, the \$124 thousand carrying value of a consumer loan was net of a \$52 thousand specific valuation allowance. The carrying value of loans fully charged-off, which includes unsecured lines of credit, overdrafts and all other loans, is zero.

When a loan is identified as impaired, it is reported at the lower of cost or fair value, measured based on the loan's observable market price (Level 1) or the current net realizable value of the underlying collateral securing the loan, if

the loan is collateral dependent (Level 3). Net realizable value of the underlying collateral is the fair value of the collateral less estimated selling costs and any prior liens. Appraisals, recent comparable sales, offers and listing prices are factored in when valuing the collateral. We review and verify the qualifications and licenses of the certified general appraisers used for appraising commercial properties or certified residential appraisers for residential properties. Real estate appraisals may utilize a combination of approaches including replacement cost, sales comparison and the income approach. Comparable sales and income data are analyzed by the appraisers and adjusted to reflect differences between them and the subject property such as property characteristics, leasing status and physical condition. When appraisals are received, Management reviews the underlying assumptions and methodology utilized, as well as the overall resulting value in conjunction with independent data sources such as recent market data and industry-wide statistics. We generally use a 6% discount for selling costs which is applied to all properties, regardless of size. Appraised values may be adjusted to reflect changes in market conditions that have occurred subsequent to the appraisal date, or for revised estimates regarding the timing or cost of the property sale. These adjustments are based on qualitative judgments made by Management on a case-by-case basis and are generally unobservable valuation

Page-11

inputs as they are specific to the underlying collateral. There have been no significant changes in the valuation techniques during 2016.

OREO represents collateral acquired through foreclosure and is initially recorded at fair value as established by a current appraisal, adjusted for disposition costs. Subsequently, OREO is measured at lower of cost or fair value. OREO values are reviewed on an ongoing basis and any subsequent decline in fair value is recorded as a foreclosed asset expense in the current period. The value of OREO is determined based on independent appraisals, similar to the process used for impaired loans, discussed above, and is classified as Level 3. All OREO resulted from an acquisition. Decreases in the estimated fair value of OREO totaled \$13 thousand and \$40 thousand during the first nine months of 2016 and 2015, respectively.

Disclosures about Fair Value of Financial Instruments

The table below is a summary of fair value estimates for financial instruments as of September 30, 2016 and December 31, 2015, excluding financial instruments recorded at fair value on a recurring basis (summarized in the first table in this note). The carrying amounts in the following table are recorded in the consolidated statements of condition under the indicated captions. We have excluded non-financial assets and non-financial liabilities defined by the Codification (ASC 820-10-15-1A), such as Bank premises and equipment, deferred taxes and other liabilities. In addition, we have not disclosed the fair value of financial instruments specifically excluded from disclosure requirements of the Financial Instruments Topic of the Codification (ASC 825-10-50-8), such as bank-owned life insurance policies ("BOLI").

(in thousands)	September 30, 2016			December 31, 2015		
	Carrying Amount	Fair Value	Fair Value Hierarchy	Carrying Amount	Fair Value	Fair Value Hierarchy
Financial assets						
Cash and cash equivalents	\$96,930	\$96,930	Level 1	\$26,343	\$26,343	Level 1
Investment securities held-to-maturity	46,423	47,867	Level 2	69,637	71,054	Level 2
Loans, net	1,451,950	1,471,861	Level 3	1,436,229	1,470,380	Level 3
Interest receivable	5,645	5,645	Level 2	6,643	6,643	Level 2
Financial liabilities						
Deposits	1,801,469	1,801,932	Level 2	1,728,226	1,728,717	Level 2
Federal Home Loan Bank and other borrowings	—	—	Level 2	67,000	67,279	Level 2
Subordinated debentures	5,540	5,156	Level 3	5,395	5,132	Level 3
Interest payable	138	138	Level 2	187	187	Level 2

Following is a description of methods and assumptions used to estimate the fair value of each class of financial instrument not recorded at fair value but required for disclosure purposes:

Cash and Cash Equivalents - The carrying amounts of cash and cash equivalents approximate their fair value because of the short-term nature of these instruments.

Held-to-maturity Securities - Held-to-maturity securities, which generally consist of obligations of state and political subdivisions and corporate bonds, are recorded at their amortized cost. The fair value for disclosure purposes is determined using methodologies similar to those described above for available-for-sale securities using Level 2 inputs. If Level 2 inputs are not available, we may utilize pricing models that incorporate unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities (Level 3). As of September 30, 2016 and December 31, 2015, we did not hold any held-to-maturity securities whose fair value was measured using significant unobservable inputs.

Loans - The fair value of loans with variable interest rates approximates their current carrying value, because their rates are regularly adjusted to current market rates. The fair value of fixed rate loans or variable loans at negotiated interest rate floors or ceilings with remaining maturities in excess of one year is estimated by discounting the future cash flows using current market rates at which similar loans would be made to borrowers with similar creditworthiness and similar remaining maturities. The allowance for loan losses (“ALLL”) is considered to be a reasonable estimate of the portion of loan discount attributable to credit risks.

Page-12

Interest Receivable and Payable - The interest receivable and payable balances approximate their fair value due to the short-term nature of their settlement dates.

Deposits - The fair value of deposits without stated maturity, such as transaction accounts, savings accounts and money market accounts, is the amount payable on demand at the reporting date. The fair value of time deposits is estimated by discounting the future cash flows using current rates offered for deposits of similar remaining maturities.

Federal Home Loan Bank Borrowings - The fair value is estimated by discounting the future cash flows using current rates offered by the Federal Home Loan Bank of San Francisco ("FHLB") for similar credit advances corresponding to the remaining term of our fixed-rate credit advances.

Subordinated Debentures - The fair values of the subordinated debentures were estimated by discounting the future cash flows (interest payment at a rate of three-month LIBOR plus 3.05% and 1.40%) to their present values using current market rates at which similar bonds would be issued with similar credit ratings as ours and similar remaining maturities. Each interest payment was discounted at the spot rate for the corresponding term, determined based on the yields and terms of comparable trust preferred securities, plus a liquidity premium. In July 2010, the Dodd-Frank Act was signed into law and limits the ability of certain bank holding companies to treat trust preferred security debt issuances as Tier 1 capital. This law effectively closed the trust-preferred securities markets for new issuances and led to the absence of observable or comparable transactions in the market place. Due to the use of unobservable inputs of trust preferred securities, we consider the fair value to be a Level 3 measurement. See Note 6 for further information.

Commitments - The value of unrecognized financial instruments is estimated based on the fee income associated with the commitments which, in the absence of credit exposure, is considered to approximate their settlement value. The fair value of commitment fees was not material at September 30, 2016 and December 31, 2015, respectively.

Note 4: Investment Securities

Our investment securities portfolio consists of obligations of state and political subdivisions, corporate bonds, U.S. government agency securities, including mortgage-backed securities ("MBS") and collateralized mortgage obligations ("CMOs") issued or guaranteed by Federal National Mortgage Association ("FNMA"), Federal Home Loan Mortgage Corporation ("FHLMC"), or Government National Mortgage Association ("GNMA"), debentures issued by government-sponsored agencies such as FNMA, Federal Farm Credit Bureau, FHLB and FHLMC, as well as privately issued CMOs, as reflected in the table below:

(in thousands)	September 30, 2016				December 31, 2015			
	Amortized Cost		Fair Value		Amortized Cost		Fair Value	
	Cost	Value	Gains	(Losses)	Cost	Value	Gains	(Losses)
Held-to-maturity:								
Obligations of state and political subdivisions	\$32,765	\$33,868	\$1,106	\$(3)	\$42,919	\$44,146	\$1,246	\$(19)
Corporate bonds	3,524	3,523	0	(1)	15,072	15,098	42	(16)
MBS pass-through securities issued by FHLMC and FNMA	10,134	10,476	342	—	11,646	11,810	171	(7)
Total held-to-maturity	46,423	47,867	1,448	(4)	69,637	71,054	1,459	(42)
Available-for-sale:								
Securities of U.S. government or government-sponsored agencies:								
MBS pass-through securities issued by FHLMC and FNMA	196,987	198,999	2,239	(227)	138,222	138,462	694	(454)
CMOs issued by FNMA	14,885	15,104	219	—	18,266	18,219	97	(144)
CMOs issued by FHLMC	30,555	30,887	332	—	22,889	22,932	82	(39)
CMOs issued by GNMA	7,654	7,834	180	—	10,326	10,480	169	(15)
Debentures of government-sponsored agencies	40,486	40,576	98	(8)	161,690	160,892	28	(826)
Privately issued CMOs	560	560	1	(1)	3,960	4,150	190	—
Obligations of state and political subdivisions	78,719	80,027	1,401	(93)	57,110	57,673	580	(17)
Corporate bonds	4,956	5,009	53	—	4,947	4,979	43	(11)
Total available-for-sale	374,802	378,996	4,523	(329)	417,410	417,787	1,883	(1,506)
Total investment securities	\$421,225	\$426,863	\$5,971	\$(333)	\$487,047	\$488,841	\$3,342	\$(1,548)

The amortized cost and fair value of investment debt securities by contractual maturity at September 30, 2016 are shown below. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to call or prepay obligations with or without call or prepayment penalties.

(in thousands)	September 30, 2016				December 31, 2015			
	Held-to-Maturity		Available-for-Sale		Held-to-Maturity		Available-for-Sale	
	Amortized Cost	Fair Value	Amortized Cost	Fair Value	Amortized Cost	Fair Value	Amortized Cost	Fair Value
Within one year	\$14,037	\$14,115	\$17,067	\$17,080	\$18,853	\$18,920	\$12,135	\$12,176
After one year but within five years	16,583	17,212	67,087	67,487	31,677	32,360	188,007	187,326
After five years through ten years	4,467	4,739	87,774	88,871	8,580	8,969	64,899	64,999
After ten years	11,336	11,801	202,873	205,558	10,527	10,805	152,369	153,286
Total	\$46,423	\$47,867	\$374,801	\$378,996	\$69,637	\$71,054	\$417,410	\$417,787

Sales of investment securities and gross realized gains and losses are shown in the following table.

(in thousands)	Three months ended		Nine months ended	
	September 30, 2015	September 30, 2016	September 30, 2015	September 30, 2015
	Available-for-sale:			

Edgar Filing: Theravance Biopharma, Inc. - Form 4

Sales proceeds	\$—	\$68,673	\$ 1,559
Gross realized gains	—	458	8
Gross realized losses	—	(64)	—

Held-to-Maturity:

Sales proceeds	\$—	\$—	\$ 1,015
Gross realized gains	—72	—	72
Gross realized losses	—	—	—

Page-14

Investment securities carried at \$70.7 million and \$87.9 million at September 30, 2016 and December 31, 2015, respectively, were pledged to the State of California: \$69.9 million and \$87.1 million to secure public deposits in compliance with the Local Agency Security Program at September 30, 2016 and December 31, 2015, respectively, and \$827 thousand and \$840 thousand to provide collateral for trust deposits at September 30, 2016 and December 31, 2015, respectively. In addition, investment securities carried at \$2.1 million and \$1.1 million were pledged to collateralize a Wealth Management and Trust Services (“WMTS”) checking account at September 30, 2016 and December 31, 2015, respectively.

Other-Than-Temporarily Impaired Debt Securities

We have evaluated the credit of our investment securities and their issuers and/or insurers. Based on our evaluation, Management has determined that no investment securities in our investment portfolio is other-than-temporarily impaired as of September 30, 2016. We do not have the intent and it is more likely than not that we will not have to sell securities temporarily impaired at September 30, 2016 before recovery of the cost basis.

Thirty-seven and fifty-four investment securities were in unrealized loss positions at September 30, 2016 and December 31, 2015, respectively. Those securities are summarized and classified according to the duration of the loss period in the tables below:

September 30, 2016 (in thousands)	< 12 continuous months		≥ 12 continuous months		Total securities in a loss position	
	Fair value	Unrealized loss	Fair value	Unrealized loss	Fair value	Unrealized loss
Held-to-maturity:						
Obligations of state and political subdivisions	\$ 547	\$ (3)	\$ —	\$ —	—\$547	\$ (3)
Corporate bonds	3,523	(1)	—	—	3,523	(1)
Total held-to-maturity	4,070	(4)	—	—	4,070	(4)
Available-for-sale:						
MBS pass-through securities issued by FHLMC and FNMA	69,229	(227)	—	—	69,229	(227)
Debentures of government- sponsored agencies	14,992	(8)	—	—	14,992	(8)
Privately issued CMOs	162	(1)	—	—	162	(1)
Obligations of state & political subdivisions	14,236	(93)	—	—	14,236	(93)
Total available-for-sale	98,619	(329)	—	—	98,619	(329)
Total temporarily impaired securities	\$ 102,689	\$ (333)	\$ —	\$ —	—\$ 102,689	\$ (333)

December 31, 2015 (in thousands)	< 12 continuous months		≥ 12 continuous months		Total securities in a loss position	
	Fair value	Unrealized loss	Fair value	Unrealized loss	Fair value	Unrealized loss
Held-to-maturity:						
Obligations of state and political subdivisions	\$8,297	\$ (19)	\$—	\$ —	\$8,297	\$ (19)
Corporate bonds	3,523	(15)	1,999	(1)	5,522	(16)
MBS pass-through securities issued by FHLMC and FNMA	2,332	(7)	—	—	2,332	(7)
Total held-to-maturity	14,152	(41)	1,999	(1)	16,151	(42)
Available-for-sale:						
MBS pass-through securities issued by FHLMC and FNMA	68,809	(454)	—	—	68,809	(454)
CMOs issued by FNMA	9,277	(80)	3,158	(64)	12,435	(144)
CMOs issued by FHLMC	—	—	1,989	(39)	1,989	(39)
CMOs issued by GNMA	164	—	2,374	(15)	2,538	(15)
Debentures of government- sponsored agencies	136,064	(713)	9,887	(113)	145,951	(826)
Obligations of state & political subdivisions	4,557	(15)	579	(2)	5,136	(17)
Corporate bonds	2,986	(11)	—	—	2,986	(11)
Total available-for-sale	221,857	(1,273)	17,987	(233)	239,844	(1,506)
Total temporarily impaired securities	\$236,009	\$ (1,314)	\$19,986	\$ (234)	\$255,995	\$ (1,548)

The thirty-seven investment securities in our portfolio in a temporary loss position for less than twelve months as of September 30, 2016 consisted of two debentures of U.S. government-sponsored agencies, twenty-three obligations of U.S. state and political subdivisions, ten MBS securities issued by government-sponsored agencies, one privately issued CMO and one corporate bond. The debentures of government-sponsored agencies are supported by the U.S. Federal Government, which protects us from credit losses. Other temporarily impaired securities are deemed creditworthy after internal analysis of the issuers' latest financial information and credit enhancement. Additionally, all are rated as investment grade by at least one major rating agency. As a result of this impairment analysis, we have concluded that these securities were not other-than-temporarily impaired at September 30, 2016.

Non-Marketable Securities

As a member of the FHLB, we are required to maintain a minimum investment in FHLB capital stock determined by the Board of Directors of the FHLB. The minimum investment requirements can increase in the event we increase our total asset size or borrowings with the FHLB. Shares cannot be purchased or sold except between the FHLB and its members at the \$100 per share par value. We held \$10.2 million and \$8.4 million of FHLB stock recorded at cost in other assets on the consolidated statements of condition at September 30, 2016 and December 31, 2015, respectively. The carrying amounts of these investments are reasonable estimates of fair value because the securities are restricted to member banks and they do not have a readily determinable market value. Management does not believe that the FHLB stock is other-than-temporarily-impaired, as we expect to be able to redeem this stock at cost. On October 19, 2016, FHLB declared a special cash dividend of \$3.41 per share on capital stock outstanding during the third quarter of 2016. In addition, on October 27, 2016, FHLB announced a cash dividend for the third quarter of 2016 at an annualized dividend rate of 8.94%. Both dividends will be distributed in mid November 2016. Cash dividends paid on FHLB capital stock are recorded as non-interest income.

As a member bank of Visa U.S.A., we hold 16,939 shares of Visa Inc. Class B common stock with a carrying value of zero, which is equal to our cost basis. These shares are restricted from resale until their conversion into Class A (voting) shares upon the termination of Visa Inc.'s covered litigation escrow account. As a result of the restriction,

these shares are not considered available-for-sale and are not carried at fair value. When converting this Class B common stock to Class A common stock under the conversion rate of 1.6483, as of the latest SEC Form 10-Q filed by Visa, Inc. on July 25, 2016, and the closing stock price of Class A shares, the value of our shares of Class B common stock would have been \$2.3 million at September 30, 2016 and \$2.2 million at December 31, 2015. The conversion

Page-16

rate is subject to further reduction upon the final settlement of the covered litigation against Visa Inc. and its member banks. See Note 8 herein.

We invest in low income housing tax credit funds as a limited partner, which totaled \$2.5 million and \$2.7 million recorded in other assets on the consolidated statements of condition at September 30, 2016 and December 31, 2015, respectively. In the first nine months of 2016, we recognized \$223 thousand of low income housing tax credits and other tax benefits, net of \$177 thousand of amortization expense of low income housing tax credit investment, as a component of income tax expense. As of September 30, 2016, our unfunded commitments for these low income housing tax credit funds totaled \$1.5 million. We did not recognize any impairment losses on these low income housing tax credit investments during the first nine months of 2016 or 2015.

Note 5: Loans and Allowance for Loan Losses

Credit Quality of Loans

Outstanding loans by class and payment aging as of September 30, 2016 and December 31, 2015 were as follows:

Loan Aging Analysis by Loan Class

(in thousands)	Commercial and industrial	Commercial real estate, owner-occupied	Commercial real estate, investor	Construction	Home equity	Other residential ¹	Installment and other consumer	Total
September 30, 2016								
30-59 days past due	\$ 2	\$ 135	\$ —	\$ —	\$ 90	\$ —	\$ 83	\$ 310
60-89 days past due	—	—	—	—	—	—	—	—
90 days or more past due	44	176	—	—	99	—	—	319
Total past due	46	311	—	—	189	—	83	629
Current	221,161	237,227	715,051	80,491	111,022	77,769	24,313	1,467,034
Total loans ³	\$ 221,207	\$ 237,538	\$ 715,051	\$ 80,491	\$ 111,211	\$ 77,769	\$ 24,396	\$ 1,467,663
Non-accrual ²	\$ 44	\$ 176	\$ —	\$ —	\$ 260	\$ —	\$ 60	\$ 540
December 31, 2015								
30-59 days past due	\$ 36	\$ —	\$ 1,096	\$ 1	\$ —	\$ —	\$ 249	\$ 1,382
60-89 days past due	—	—	—	—	633	—	89	722
90 days or more past due	21	—	—	—	99	—	—	120
Total past due	57	—	1,096	1	732	—	338	2,224
Current	219,395	242,309	714,783	65,494	111,568	73,154	22,301	1,449,004
Total loans ³	\$ 219,452	\$ 242,309	\$ 715,879	\$ 65,495	\$ 112,300	\$ 73,154	\$ 22,639	\$ 1,451,228
Non-accrual ²	\$ 21	\$ —	\$ 1,903	\$ 1	\$ 171	\$ —	\$ 83	\$ 2,179

¹ Our residential loan portfolio does not include sub-prime loans, nor is it our practice to underwrite loans commonly referred to as "Alt-A mortgages", the characteristics of which are loans lacking full documentation, borrowers having low FICO scores or higher loan-to-value ratios.

² Amounts include \$1 thousand of purchased credit impaired ("PCI") loans that had stopped accruing interest at December 31, 2015. Amounts exclude accruing PCI loans of \$2.9 million and \$3.7 million at September 30, 2016 and December 31, 2015, respectively, as we have a reasonable expectation about future cash flows to be collected and we continue to recognize accretible yield on these loans in interest income. These accruing PCI loans are included in current loans. There were no accruing loans more than ninety days past due at September 30, 2016 or December 31, 2015.

³ Amounts include net deferred loan costs of \$869 thousand and \$768 thousand at September 30, 2016 and December 31, 2015, respectively. Amounts are also net of unaccrued purchase discounts on non-PCI loans of \$1.9

million and \$3.2 million at September 30, 2016 and December 31, 2015, respectively.

Our commercial loans are generally made to established small and mid-sized businesses to provide financing for their growth and working capital needs, equipment purchases and/or acquisitions. Management examines historical, current, and projected cash flows to determine the ability of the borrower to repay obligations as agreed. Commercial loans are made based primarily on the identified cash flows of the borrower and secondarily on the underlying collateral and/or guarantor support. The cash flows of borrowers, however, may not occur as expected, and the collateral securing these loans may fluctuate in value. Most commercial and industrial loans are secured by the assets being financed, such as accounts receivable and/or inventory, and typically include a personal guarantee. We target stable businesses with guarantors that have proven to be resilient in periods of economic stress. Typically, the guarantors provide an additional source of repayment for most of our credit extensions.

Commercial real estate loans are subject to underwriting standards and processes similar to commercial loans discussed above. We underwrite these loans to be repaid from cash flow and to be supported by real property collateral. Underwriting standards for commercial real estate loans include, but are not limited to, debt coverage and loan-to-value ratios. Furthermore, the vast majority of our loans are guaranteed by the owners of the properties. Commercial

Page-17

real estate loans may be adversely affected by conditions in the real estate markets or in the general economy. In the event of a vacancy, guarantors are expected to carry the loans until a replacement tenant can be found. Regardless of the guaranty status, the owner's equity investment provides a strong economic incentive to continue to support the commercial real estate projects. As such, we have experienced a low level of loss and delinquencies in this portfolio.

Construction loans are generally made to developers and builders to finance construction, renovation and occasionally land acquisitions in anticipation of near-term development. These loans are underwritten after evaluation of the borrower's financial strength, reputation, prior track record, and independent appraisals. The construction industry can be affected by significant events, including: the inherent volatility of real estate markets and vulnerability to delays due to weather, change orders, inability to obtain construction permits, labor or material shortages, and price changes. Estimates of construction costs and value associated with the completed project may be inaccurate. Repayment of construction loans is largely dependent on the ultimate success of the project.

Consumer loans primarily consist of home equity lines of credit, other residential (tenancy-in-common, or "TIC") loans, and installment and other consumer loans. We originate consumer loans utilizing credit score information, debt-to-income ratio and loan-to-value ratio analysis. Diversification, coupled with relatively small loan amounts that are spread across many individual borrowers, mitigates risk. Additionally, trend reports are reviewed by Management on a regular basis. Our residential loan portfolio includes TIC units almost entirely in San Francisco. Installment and other consumer loans include mostly loans for floating homes and mobile homes along with a small number of installment loans.

We use a risk rating system to evaluate asset quality, and to identify and monitor credit risk in individual loans, and ultimately in the portfolio. Definitions of loans that are risk graded "Special Mention" or worse are consistent with those used by the Federal Deposit Insurance Corporation ("FDIC"). Our internally assigned grades are as follows:

Pass: Loans to borrowers of acceptable or better credit quality. Borrowers in this category demonstrate fundamentally sound financial positions, repayment capacity, credit history and management expertise. Loans in this category must have an identifiable and stable source of repayment and meet the Bank's policy regarding debt service coverage ratios. These borrowers are capable of sustaining normal economic, market or operational setbacks without significant financial consequences. Negative external industry factors are generally not present. The loan may be secured, unsecured or supported by non-real estate collateral for which the value is more difficult to determine and/or marketability is more uncertain. This category also includes "Watch" loans, where the primary source of repayment has been delayed. "Watch" is intended to be a transitional grade, with either an upgrade or downgrade within a reasonable period.

Special Mention: Potential weaknesses that deserve close attention. If left uncorrected, those potential weaknesses may result in deterioration of the payment prospects for the asset. Special Mention assets do not present sufficient risk to warrant adverse classification.

Substandard: Inadequately protected by either the current sound worth and paying capacity of the obligor or the collateral pledged, if any. A Substandard asset has a well-defined weakness or weaknesses that jeopardize(s) the liquidation of the debt. Substandard assets are characterized by the distinct possibility that we will sustain some loss if such weaknesses or deficiencies are not corrected. Well-defined weaknesses include adverse trends or developments in the borrower's financial condition, managerial weaknesses and/or significant collateral deficiencies.

Doubtful: Critical weaknesses that make collection or liquidation in full improbable. There may be specific pending events that work to strengthen the asset; however, the amount or timing of the loss may not be determinable. Pending events generally occur within one year of the asset being classified as Doubtful. Examples include: merger, acquisition, or liquidation; capital injection; guarantee; perfecting liens on additional collateral; and refinancing. Such

loans are placed on non-accrual status and usually are collateral-dependent.

We regularly review our credits for accuracy of risk grades whenever new information is received. Borrowers are required to submit financial information at regular intervals:

- Generally, commercial borrowers with lines of credit are required to submit financial information with reporting intervals ranging from monthly to annually depending on credit size, risk and complexity.

- Investor commercial real estate borrowers are generally required to submit rent rolls or property income statements annually.

- Construction loans are monitored monthly, and reviewed on an ongoing basis.

Page-18

Home equity and other consumer loans are reviewed based on delinquency.

Loans graded "Watch" or more severe, regardless of loan type, are reviewed no less than quarterly.

The following table represents an analysis of loans by internally assigned grades, including the PCI loans, at September 30, 2016 and December 31, 2015:

Credit Risk Profile by Internally Assigned Grade

(in thousands)	Commercial and industrial	Commercial real estate, owner-occupied	Commercial real estate, investor	Construction	Home equity	Other residential	Installment and other consumer	Purchased credit-impaired	Total
September 30, 2016									
Pass	\$ 203,784	\$ 224,502	\$ 711,192	\$ 77,253	\$ 108,908	\$ 77,769	\$ 23,976	\$ 2,874	\$ 1,430,258
Special Mention	8,859	4,478	356	—	1,120	—	—	—	14,813
Substandard	8,524	7,505	1,793	3,238	1,112	—	420	—	22,592
Total loans	\$ 221,167	\$ 236,485	\$ 713,341	\$ 80,491	\$ 111,140	\$ 77,769	\$ 24,396	\$ 2,874	\$ 1,467,663
December 31, 2015									
Pass	\$ 192,560	\$ 219,060	\$ 710,042	\$ 62,255	\$ 109,959	\$ 73,154	\$ 22,307	\$ 3,260	\$ 1,392,597
Special Mention	22,457	12,371	372	—	1,100	—	—	—	36,300
Substandard	4,260	9,167	3,739	3,239	1,173	—	332	421	22,331
Total loans	\$ 219,277	\$ 240,598	\$ 714,153	\$ 65,494	\$ 112,232	\$ 73,154	\$ 22,639	\$ 3,681	\$ 1,451,228

Troubled Debt Restructuring

Our loan portfolio includes certain loans that have been modified in a troubled debt restructuring ("TDR"), where economic concessions have been granted to borrowers experiencing financial difficulties. These concessions typically result from our loss mitigation activities and could include reductions in the interest rate, payment extensions, forgiveness of principal, forbearance or other actions. TDRs on non-accrual status at the time of restructure may be returned to accruing status after Management considers the borrower's sustained repayment performance for a reasonable period, generally six months, and obtains reasonable assurance of repayment and performance.

A loan may no longer be reported as a TDR if all of the following conditions are met:

- The loan is subsequently refinanced or restructured at current market interest rates and the new terms are consistent with the treatment of creditworthy borrowers under regular underwriting standards;
- The borrower is no longer considered to be in financial difficulty;
- Performance on the loan is reasonably assured; and;
- Existing loan did not have any forgiveness of principal or interest.

The removal of TDR status must be approved by the same management level that approved the upgrading of the loan classification.

There were no loans removed from TDR designation during 2016. During the first nine months of 2015, four loans with a recorded investment totaling \$1.4 million were removed from TDR designation as they met our criteria outlined above.

The table below summarizes outstanding TDR loans by loan class as of September 30, 2016 and December 31, 2015. The summary includes both TDRs that are on non-accrual status and those that continue to accrue interest. (in thousands)

Recorded investment in Troubled Debt Restructurings ¹	September	December
	30, 2016	31, 2015
Commercial and industrial	\$2,964	\$4,698
Commercial real estate, owner-occupied	6,993	6,993
Commercial real estate, investor	2,299	514
Construction ²	3,238	3,238
Home equity	696	460
Other residential	1,974	2,010
Installment and other consumer	1,024	1,168
Total	\$19,188	\$19,081

¹ Includes \$19.1 million and \$19.0 million of TDR loans that were accruing interest as of September 30, 2016 and December 31, 2015, respectively. Includes no acquired loans at September 30, 2016 and \$137 thousand of acquired loans at December 31, 2015.

² In June 2015, one TDR loan was transferred to loans held-for-sale at fair value totaling \$1.5 million, net of an \$839 thousand charge-off to the allowance for loan losses. The loan was subsequently sold in June 2015 for no additional gain or loss.

The table below presents the following information for loans modified in a TDR during the presented periods: number of contracts modified, the recorded investment in the loans prior to modification, and the recorded investment in the loans after being restructured. The table below excludes fully charged-off TDR loans and loans modified in a TDR and subsequently paid-off during the years presented.

(dollars in thousands)	Number of Contracts Modified	Pre-Modification	Post-Modification	Post-Modification
		Outstanding Recorded Investment	Outstanding Recorded Investment	Outstanding Recorded Investment at Period End
Troubled Debt Restructurings during the three months ended September 30, 2016:				
None	—	\$ —	\$ —	\$ —
Troubled Debt Restructurings during the three months ended September 30, 2015:				
Commercial and industrial	1	\$ 700	\$ 700	\$ 700
Troubled Debt Restructurings during the nine months ended September 30, 2016:				
Commercial real estate, investor		2\$1,830	\$1,826	\$1,808
Home equity ¹		187	222	222
Total		3\$1,917	\$2,048	\$2,030
Troubled Debt Restructurings during the nine months ended September 30, 2015:				
Commercial and industrial		5\$1,482	\$1,582	\$1,463
Commercial real estate, investor		1222	221	217
Total		6\$1,704	\$1,803	\$1,680

¹ The home equity TDR modification during the second quarter of 2016 included debt consolidation which increased the post-modification balance.

Modifications during the nine months ended September 30, 2016 primarily involved interest rate concessions, renewals, and other changes to loan terms. Modifications during the nine months ended September 30, 2015 primarily involved maturity extensions and other changes to loan terms. During the first nine months of 2016 and 2015, there were no defaults on loans that had been modified in a TDR within the prior twelve-month period. We report defaulted TDRs based on a payment default definition of more than ninety days past due.

Page-20

Impaired Loan Balances and Their Related Allowance by Major Classes of Loans

The tables below summarize information on impaired loans and their related allowance. Total impaired loans include non-accrual loans, accruing TDR loans and accreting PCI loans that have experienced post-acquisition declines in cash flows expected to be collected.

(in thousands)	Commercial and industrial	Commercial real estate, owner-occupied	Commercial real estate, investor	Construction	Home equity	Other residential	Installment and other consumer	Total
September 30, 2016								
Recorded investment in impaired loans:								
With no specific allowance recorded	\$ 1,102	\$ —	\$ —	\$ 2,688	\$ 260	\$ 1,189	\$ 108	\$ 5,347
With a specific allowance recorded	1,906	7,169	2,299	550	625	785	976	14,310
Total recorded investment in impaired loans	\$ 3,008	\$ 7,169	\$ 2,299	\$ 3,238	\$ 885	\$ 1,974	\$ 1,084	\$ 19,657
Unpaid principal balance of impaired loans	\$ 3,008	\$ 7,169	\$ 2,299	\$ 3,238	\$ 885	\$ 1,974	\$ 1,084	\$ 19,657
Specific allowance	569	108	474	5	34	59	94	1,343
Average recorded investment in impaired loans during the quarter ended September 30, 2016	3,352	7,169	3,146	3,238	1,140	1,981	1,113	21,139
September 30, 2016								
Interest income recognized on impaired loans during the quarter ended September 30, 2016 ¹	44	67	1,385	32	38	22	12	1,600
Average recorded investment in impaired loans during the nine months ended September 30, 2016	3,802	7,081	3,397	3,238	1,098	1,993	1,179	21,788
September 30, 2016								
Interest income recognized on impaired loans during the nine months ended September 30, 2016 ¹	142	133	1,489	105	48	67	37	2,021
Average recorded investment in impaired loans during the quarter ended September 30, 2015	4,473	7,695	2,886	3,262	610	2,025	1,439	22,390
September 30, 2015								
Interest income recognized on impaired loans during the quarter ended September 30, 2015	58	84	10	22	5	23	15	217
Average recorded investment in impaired loans during the nine months ended September 30, 2015	4,121	8,183	2,916	4,473	616	2,033	1,579	23,921
September 30, 2015								
Interest income recognized on impaired loans during the nine months ended September 30, 2015	176	228	24	40	14	69	51	602

¹ Interest income recognized on a cash basis totaled \$1.4 million for the three and nine months ended September 30, 2016 and was primarily related to the interest recovery upon the pay-off of a partially charged off non-accrual commercial real estate loan during the third quarter. No interest income on impaired loans was recognized on a cash basis during the three and nine months ended September 30, 2015.

(in thousands)

Explanation of Responses:

Edgar Filing: Theravance Biopharma, Inc. - Form 4

	Commercial and industrial	Commercial real estate, owner-occupied	Commercial real estate, investor		Home equity	Other residential	Installment and other consumer	
December 31, 2015								
Recorded investment in impaired loans:								
With no specific allowance recorded	\$ 2,198	\$ 4,111	\$ 2,416	\$ 2,687	\$ 171	\$ 1,214	\$ 131	\$ 12,928
With a specific allowance recorded	2,522	2,882	—	551	388	797	1,120	8,260
Total recorded investment in impaired loans	\$ 4,720	\$ 6,993	\$ 2,416	\$ 3,238	\$ 559	\$ 2,011	\$ 1,251	\$ 21,188
Unpaid principal balance of impaired loans	\$ 4,763	\$ 6,993	\$ 4,408	\$ 3,424	\$ 559	\$ 2,011	\$ 1,251	\$ 23,409
Specific allowance	\$ 912	\$ 70	\$ —	\$ 1	\$ 3	\$ 67	\$ 116	\$ 1,169

Management monitors delinquent loans continuously and identifies problem loans, generally loans graded substandard or worse, to be evaluated individually for impairment testing. Generally, the recorded investment in impaired loans is net of any charge-offs from estimated losses related to specifically-identified impaired loans when they are deemed uncollectible. There were no amounts charged off for impaired loans outstanding at September 30, 2016. The charged-off portion of impaired loans outstanding at December 31, 2015 totaled \$2.1 million. In addition, the recorded investment in impaired loans is net of purchase discounts or premiums on acquired loans. At both September 30, 2016 and December 31, 2015, unused commitments to extend credit on impaired loans, including loans to borrowers whose terms have been modified in TDRs, totaled \$1.3 million.

Edgar Filing: Theravance Biopharma, Inc. - Form 4

The following tables disclose loans by major portfolio category and activity in the ALLL, as well as the related ALLL disaggregated by impairment evaluation method.

Allowance for Loan Losses Rollforward for the Period

(in thousands)	Commercial and industrial	Commercial real estate, owner-occupied	Commercial real estate, investor	Construction	Home equity	Other residential	Installment and other consumer	Unallocated	Total
Three months ended September 30, 2016									
Allowance for loan losses:									
Beginning balance	\$ 2,637	\$ 1,631	\$ 6,595	\$ 831	\$1,076	\$ 426	\$ 437	\$ 1,454	\$15,087
Provision (reversal)	828	(10)(2,416) 105	(125)22	(73) 119	(1,550
Charge-offs	—	—	—	—	—	—	—	—	—
Recoveries	29	—	2,146	—	1	—	—	—	2,176
Ending balance	\$ 3,494	\$ 1,621	\$ 6,325	\$ 936	\$952	\$ 448	\$ 364	\$ 1,573	\$15,713

Three months ended September 30, 2015

Allowance for loan losses:									
Beginning balance	\$ 2,540	\$ 2,052	\$ 5,944	\$ 535	\$843	\$ 435	\$ 444	\$ 1,561	\$14,354
Provision (reversal)	86	17	128	158	9	(50) 32	(380) —
Charge-offs	(2) —	—	—	—	—	(1) —	(3
Recoveries	92	—	12	—	1	—	1	—	106
Ending balance	\$ 2,716	\$ 2,069	\$ 6,084	\$ 693	\$853	\$ 385	\$ 476	\$ 1,181	\$14,457

Allowance for Loan Losses Rollforward for the Period

(in thousands)	Commercial and industrial	Commercial real estate, owner-occupied	Commercial real estate, investor	Construction	Home equity	Other residential	Installment and other consumer	Unallocated	Total
Nine months ended September 30, 2016									
Allowance for loan losses:									
Beginning balance	\$ 3,023	\$ 2,249	\$ 6,178	\$ 724	\$910	\$ 394	\$ 425	\$ 1,096	\$14,999
Provision (reversal)	388	(628)(2,009) 212	40	54	(84) 477	(1,550
Charge-offs	(9) —	—	—	—	—	(4) —	(13
Recoveries	92	—	2,156	—	2	—	27	—	2,277
Ending balance	\$ 3,494	\$ 1,621	\$ 6,325	\$ 936	\$952	\$ 448	\$ 364	\$ 1,573	\$15,713

Nine months ended September 30, 2015

Allowance for loan losses:									
Beginning balance	\$ 2,837	\$ 1,924	\$ 6,672	\$ 839	\$859	\$ 433	\$ 566	\$ 969	\$15,099
Provision (reversal)	(306) 145	(606) 693	(9)(48) (81) 212	—
Charge-offs	(5) —	—	(839) —	—	(12) —	(856
Recoveries	190	—	18	—	3	—	3	—	214
Ending balance	\$ 2,716	\$ 2,069	\$ 6,084	\$ 693	\$853	\$ 385	\$ 476	\$ 1,181	\$14,457

Edgar Filing: Theravance Biopharma, Inc. - Form 4

Allowance for Loan Losses and Recorded Investment in Loans

(dollars in thousands)	Commercial and industrial	Commercial real estate, owner-occupied	Commercial real estate, investor	Construction	Home equity	Other residential	Installment and other consumer	Unallocated	Total
September 30, 2016									
Ending ALLL related to loans collectively evaluated for impairment	\$2,925	\$1,513	\$5,851	\$931	\$918	\$389	\$270	\$1,573	\$14,370
Ending ALLL related to loans individually evaluated for impairment	569	108	474	5	34	59	94	—	1,343
Ending ALLL related to purchased credit-impaired loans	—	—	—	—	—	—	—	—	—
Total	\$3,494	\$1,621	\$6,325	\$936	\$952	\$448	\$364	\$1,573	\$15,713
Loans outstanding:									
Collectively evaluated for impairment	\$218,159	\$229,316	\$711,042	\$77,253	\$110,255	\$75,795	\$23,312	\$—	\$1,445,132
Individually evaluated for impairment	3,008	7,169	2,299	3,238	885	1,974	1,084	—	19,657
Purchased credit-impaired	40	1,053	1,710	—	71	—	—	—	2,874
Total	\$221,207	\$237,538	\$715,051	\$80,491	\$111,211	\$77,769	\$24,396	\$—	\$1,467,663
Ratio of allowance for loan losses to total loans	1.58	%0.68	%0.88	%1.16	%0.86	%0.58	%1.49	%NM	1.07
Allowance for loan losses to non-accrual loans	7,941	%921	%NM	NM	366	%NM	607	%NM	2,910

NM - Not Meaningful

Allowance for Loan Losses and Recorded Investment in Loans

(dollars in thousands)	Commercial and industrial	Commercial real estate, owner-occupied	Commercial real estate, investor	Construction	Home equity	Other residential	Installment and other consumer	Unallocated	Total
December 31, 2015									
Ending ALLL related to loans collectively evaluated for impairment	\$2,111	\$2,179	\$6,178	\$723	\$907	\$327	\$309	\$1,096	\$13,830
Ending ALLL related to loans individually evaluated for impairment	904	70	—	—	3	67	116	—	1,160
Ending ALLL related to purchased credit-impaired loans	8	—	—	1	—	—	—	—	9
Total	\$3,023	\$2,249	\$6,178	\$724	\$910	\$394	\$425	\$1,096	\$14,999
Loans outstanding:									
Collectively evaluated for impairment	\$214,695	\$233,605	\$711,737	\$62,256	\$111,673	\$71,143	\$21,388	\$—	\$1,426,497
Individually evaluated for impairment ¹	4,582	6,993	2,416	3,238	559	2,011	1,251	—	21,050

Explanation of Responses:

Edgar Filing: Theravance Biopharma, Inc. - Form 4

Purchased credit-impaired	175	1,711	1,726	1	68	—	—	—	3,681
Total	\$219,452	\$242,309	\$715,879	\$65,495	\$112,300	\$73,154	\$22,639	\$—	\$1,451,228
Ratio of allowance for loan losses to total loans	1.38	%0.93	%0.86	%1.11	%0.81	%0.54	%1.88	%NM	1.03
Allowance for loan losses to non-accrual loans	14,395	%NM	325	%72,400	%532	%NM	512	%NM	688

¹ Total excludes \$138 thousand PCI loans as of December 31, 2015 that have experienced credit deterioration post-acquisition declines in cash flows expected to be collected. These loans are included in the "purchased credit-impaired" amount in the next line below.

NM - Not Meaningful

Purchased Credit-Impaired Loans

We evaluated loans purchased in acquisitions in accordance with accounting guidance in ASC 310-30 related to loans acquired with deteriorated credit quality. Acquired loans are considered credit-impaired if there is evidence of significant deterioration of credit quality since origination and it is probable, at the acquisition date, that we will be unable to collect all contractually required payments receivable. Management has determined certain loans purchased in our two acquisitions to be PCI loans based on credit indicators such as non-accrual status, past due status, loan risk grade,

loan-to-value ratio, etc. Revolving credit agreements (e.g., home equity lines of credit and revolving commercial loans) are not considered PCI loans as cash flows cannot be reasonably estimated.

For acquired loans not considered credit-impaired, the difference between the contractual amounts due (principal amount) and the fair value is accounted for subsequently through accretion. We recognize discount accretion based on the acquired loan's contractual cash flows using an effective interest rate method. The accretion is recognized through the net interest margin.

The following table presents the outstanding balances and related carrying values of PCI loans as of September 30, 2016 and December 31, 2015.

PCI Loans (in thousands)	September 30, 2016		December 31, 2015	
	Unpaid principal balance	Carrying value	Unpaid principal balance	Carrying value
Commercial and industrial	\$47	\$40	\$237	\$175
Commercial real estate	3,080	2,763	4,329	3,437
Construction	—	—	187	1
Home equity	220	71	224	68
Total purchased credit-impaired loans	\$3,347	\$2,874	\$4,977	\$3,681

The activities in the accretable yield, or income expected to be earned, for PCI loans were as follows:

Accretable Yield (in thousands)	Three months ended		Nine months ended	
	September 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015
Balance at beginning of period	\$1,655	\$3,711	\$2,618	\$4,027
Removals ¹	—	(837)	(778)	(914)
Accretion	(89)	(128)	(274)	(367)
Reclassifications from nonaccretable difference ²	—	—	—	—
Balance at end of period	\$1,566	\$2,746	\$1,566	\$2,746

¹ Represents the accretable difference that is relieved when a loan exits the PCI population due to pay-off, full charge-off, or transfer to repossessed assets, etc.

² Primarily relates to changes in expected credit performance and changes in expected timing of cash flows.

Pledged Loans

Our FHLB line of credit is secured under terms of a blanket collateral agreement by a pledge of certain qualifying loans with an unpaid principal balance of \$863.2 million and \$833.8 million at September 30, 2016 and December 31, 2015, respectively. In addition, we pledge a certain residential loan portfolio, which totaled \$48.7 million and \$45.2 million at September 30, 2016 and December 31, 2015, respectively, to secure our borrowing capacity with the Federal Reserve Bank of San Francisco. Also see Note 6, Borrowings.

Note 6: Borrowings

Federal Funds Purchased – The Bank had unsecured lines of credit totaling \$92.0 million with correspondent banks for overnight borrowings at September 30, 2016 and December 31, 2015. In general, interest rates on these lines approximate the federal funds target rate. We had no overnight borrowings under these credit facilities at September 30, 2016 and December 31, 2015.

Federal Home Loan Bank Borrowings – As of September 30, 2016 and December 31, 2015, the Bank had lines of credit with the FHLB totaling \$487.6 million and \$470.6 million, respectively, based on eligible collateral of certain loans. At September 30, 2016, we had no FHLB overnight borrowings and at December 31, 2015, we had \$52.0 million in FHLB overnight borrowings. On February 5, 2008, the Bank entered into a ten-year borrowing agreement under the same FHLB line of credit for \$15.0 million at a fixed rate of 2.07%. On June 15, 2016, the Bank repaid the \$15.0 million early and incurred a prepayment fee of \$312 thousand recorded in interest expense. At September 30, 2016 and December 31, 2015, \$487.6 million and \$403.4 million, respectively, were remaining as available for borrowing from the FHLB, net of the overnight borrowings and term borrowings.

Federal Reserve Line of Credit – The Bank has a line of credit with the Federal Reserve Bank of San Francisco ("FRBSF") secured by certain residential loans. At September 30, 2016 and December 31, 2015, the Bank had

Page-24

borrowing capacity under this line totaling \$38.8 million and \$37.8 million, respectively, and had no outstanding borrowings with the FRBSF.

As part of an acquisition, Bancorp assumed two subordinated debentures due to NorCal Community Bancorp Trusts I and II (the "Trusts"), established for the sole purpose of issuing trust preferred securities on September 22, 2003 and December 29, 2005, respectively. The subordinated debentures were recorded at fair values totaling \$4.95 million at acquisition date with contractual values totaling \$8.2 million. The difference between the contractual balance and the fair value at acquisition date is accreted into interest expense over the lives of the debentures. Accretion on the subordinated debentures totaled \$145 thousand in the first nine months of 2016 and \$158 thousand in the first nine months of 2015. Bancorp has the option to defer payment of the interest on the subordinated debentures for a period of up to five years, as long as there is no default on the subordinated debentures. In the event of interest deferral, dividends to Bancorp common stockholders are prohibited. The trust preferred securities were sold and issued in private transactions pursuant to an exemption from registration under the Securities Act of 1933, as amended. Bancorp has guaranteed, on a subordinated basis, distributions and other payments due on trust preferred securities totaling \$8.0 million issued by the Trusts which have identical maturity, repricing and payment terms as the subordinated debentures.

The following is a summary of the contractual terms of the subordinated debentures due to the Trusts as of September 30, 2016:

(in thousands)

Subordinated debentures due to NorCal Community Bancorp Trust I on October 7, 2033 with interest payable quarterly, based on 3-month LIBOR plus 3.05%, repricing quarterly (3.73% as of September 30, 2016), redeemable, in whole or in part, on any interest payment date	\$4,124
Subordinated debentures due to NorCal Community Bancorp Trust II on March 15, 2036 with interest payable quarterly, based on 3-month LIBOR plus 1.40%, repricing quarterly (2.25% as of September 30, 2016), redeemable, in whole or in part, on any interest payment date	4,124
Total	\$8,248

Note 7: Stockholders' Equity

Warrant

Under the United States Department of the Treasury Capital Purchase Program (the "TCPP"), Bancorp issued to the U.S. Treasury a warrant to purchase 154,242 shares of common stock at a per share exercise price of \$27.23. The warrant was immediately exercisable and had an expiration date of December 5, 2018. The warrant was subsequently auctioned to two institutional investors in November 2011 and was exercised in September 2015. The warrant represented the right to purchase 157,711 shares of common stock at \$26.63 per share. The cashless exercise resulted in the net issuance of 70,591 shares of common stock in September 2015.

Dividends

Presented below is a summary of cash dividends paid to common shareholders, recorded as a reduction of retained earnings.

(in thousands, except per share data)	Three months ended		Nine months ended	
	September 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015
Cash dividends to common stockholders	\$ 1,528	\$ 1,316	\$ 4,573	\$ 3,936
Cash dividends per common share	\$ 0.25	\$ 0.22	\$ 0.75	\$ 0.66

The Board of Directors declared a cash dividend of \$0.27 per share on October 21, 2016 payable on November 14, 2016 to shareholders of record at the close of business on November 4, 2016.

Page-25

Share-Based Payments

The fair value of stock options as of the grant date is recorded as stock-based compensation expense in the consolidated statements of comprehensive income over the requisite service period with a corresponding increase in common stock. Stock-based compensation also includes compensation expense related to the issuance of unvested restricted stock awards and performance-based stock awards pursuant to the 2007 Equity Plan. The grant-date fair value of the restricted stock awards and performance-based stock awards, which is equal to the intrinsic value on that date, is being recorded as compensation expense over the requisite service period with a corresponding increase in common stock as the shares vest.

Beginning in 2015, performance-based stock awards were issued to a selected group of employees. Stock award vesting is contingent upon the achievement of pre-established long-term performance goals set by the Compensation Committee of the Board of Directors. Performance is measured over a three-year period and cliff vested. These performance-based stock awards were granted at a maximum opportunity level, and based on the achievement of the pre-established goals, the actual payouts can range from 0% to 200% of the target award. For performance-based stock awards, an estimate is made of the number of shares expected to vest based on the probability that the performance criteria will be achieved to determine the amount of compensation expense to be recognized. The estimate is re-evaluated quarterly and total compensation expense is adjusted for any change in the current period.

In addition, we record excess tax benefits on the exercise of non-qualified stock options, the disqualifying disposition of incentive stock options and vesting of restricted stock awards as an addition to common stock with a corresponding decrease in current taxes payable.

The holders of unvested restricted stock awards and performance-based stock awards are entitled to dividends on the same per-share ratio as holders of common stock. Dividends paid on the portion of share-based awards not expected to vest are also included in stock-based compensation expense. Tax benefits on dividends paid on the portion of share-based awards expected to vest are recorded as an increase to common stock with a corresponding decrease in current taxes payable.

Note 8: Commitments and Contingencies

Financial Instruments with Off-Balance Sheet Risk

We make commitments to extend credit in the normal course of business to meet the financing needs of our customers. These financial instruments include commitments to extend credit in the form of loans or through standby letters of credit. Commitments to extend credit are agreements to lend to a customer as long as there is no violation of any condition established in the contract. Commitments generally have fixed expiration dates or other termination clauses and may require payment of a fee. Because various commitments will expire without being fully drawn upon, the total commitment amount does not necessarily represent future cash requirements.

We are exposed to credit loss equal to the contractual amount of the commitment in the event of nonperformance by the borrower. We use the same credit underwriting criteria for all credit exposure. The amount of collateral obtained, if deemed necessary by us, is based on Management's credit evaluation of the borrower. Collateral types pledged may include accounts receivable, inventory, other personal property and real property.

The contractual amount of undrawn loan commitments and standby letters of credit not reflected on the consolidated statements of condition was \$416.5 million and \$376.6 million at September 30, 2016 and December 31, 2015, respectively. Commitments at September 30, 2016 included \$212.6 million under commercial lines of credit (these commitments are generally contingent upon customers maintaining specific credit standards), \$149.0 million under

revolving home equity lines, \$40.7 million under construction loans, \$3.5 million under standby letters of credit, and a remaining \$10.7 million under personal and other lines of credit. We record an allowance for losses on these off-balance sheet commitments based on an estimate of probabilities of these commitments being drawn upon according to our historical utilization experience on different types of commitments and expected loss severity. We set aside an allowance for losses on off-balance sheet commitments in the amount of \$899 thousand and \$749 thousand as of September 30, 2016 and December 31, 2015, respectively, which is recorded in interest payable and other liabilities on the consolidated statements of condition. The increase in the reserve for off-balance sheet commitments for the first nine months of 2016 was primarily due to an increase in commitments and a decrease in utilization.

Operating Leases

We rent certain premises and equipment under long-term, non-cancelable operating leases expiring at various dates through the year 2032. Most of the leases contain certain renewal options and escalation clauses. At September 30, 2016, the approximate minimum future commitments payable under non-cancelable contracts for leased premises are as follows:

(in thousands)	2016	2017	2018	2019	2020	Thereafter	Total
Operating leases ¹	\$903	\$3,832	\$3,898	\$3,707	\$3,385	\$ 6,321	\$22,046

¹ Minimum payments have not been reduced by minimum sublease rentals of \$175 thousand due in the future under non-cancelable subleases.

Rent expense included in occupancy expense totaled \$2.8 million and \$3.2 million for the nine months ended September 30, 2016 and 2015, respectively.

Litigation Matters

We may be party to legal actions which arise from time to time as part of the normal course of our business. We believe, after consultation with legal counsel, that we have meritorious defenses in these actions, and that litigation contingent liability, if any, will not have a material adverse effect on our financial position, results of operations, or cash flows.

We are responsible for our proportionate share of certain litigation indemnifications provided to Visa U.S.A. ("Visa") by its member banks in connection with lawsuits related to anti-trust charges and interchange fees ("Covered Litigation"). Visa maintains an escrow account from which settlements of, or judgments in, the Covered Litigation are paid. While the accrual related to the Covered Litigation could be higher or lower than the litigation escrow account balance, Visa did not record an additional accrual for the Covered Litigation during 2016. At June 30, 2016, according to the latest SEC Form 10-Q filed by Visa, Inc. on July 25, 2016, the balance of the escrow account was \$1.0 billion. Visa had reached a \$4.0 billion interchange multidistrict litigation class settlement agreement. However, a number of objectors have appealed and on June 30, 2016, an appellate court reversed the approval of the settlement by the lower court. Until the appeal process is complete, Visa is uncertain whether it will resolve the claims as contemplated by the settlement agreement and additional lawsuits may arise. The conversion rate of Visa Class B common stock held by us to Class A common stock (as discussed in Note 4, Investment Securities) may decrease if Visa makes more Covered Litigation settlement payments in the future, and the full effect on member banks is still uncertain. However, we are not aware of significant future cash settlement payments required by us on the Covered Litigation.

Note 9: Derivative Financial Instruments and Hedging Activities

We have entered into interest rate swap agreements, primarily as an asset/liability management strategy, in order to mitigate the changes in the fair value of specified long-term fixed-rate loans (or firm commitments to enter into long-term fixed-rate loans) caused by changes in interest rates. These hedges allow us to offer long-term fixed-rate loans to customers without assuming the interest rate risk of a long-term asset. Converting our fixed-rate interest payments to floating-rate interest payments, generally benchmarked to the one-month U.S. dollar LIBOR index, protects us against changes in the fair value of our loans associated with fluctuating interest rates.

The fixed-rate payment features of the interest rate swap agreements are generally structured at inception to mirror substantially all of the provisions of the hedged loan agreements. These interest rate swaps, designated and qualified as fair value hedges, are carried on the consolidated statements of condition at their fair value in other assets (when the fair value is positive) or in other liabilities (when the fair value is negative). The unrealized gain or loss in fair value of the hedged fixed-rate loan due to LIBOR interest rate movements is recorded as an adjustment to the hedged loan.

From time to time, we make firm commitments to enter into long-term fixed-rate loans with borrowers backed by yield maintenance agreements and simultaneously enter into forward interest rate swap agreements with correspondent banks to mitigate the change in fair value of the yield maintenance agreement. Prior to loan funding, yield maintenance agreements with net settlement features that meet the definition of a derivative are considered as non-designated hedges and are carried on the consolidated statements of condition at their fair value in other assets (when the fair value is positive) or in other liabilities (when the fair value is negative). The offsetting changes in the fair value of the forward swap and the yield maintenance agreement are recorded in interest income. When the fixed-rate loans are originated, the forward swaps are designated to offset the change in fair value in the loans. Subsequent to the point

Page-27

of the swap designations, the related yield maintenance agreements are no longer considered derivatives. Their fair value at the designation date is recorded in other assets and is amortized using the effective yield method over the life of the respective designated loans.

The net effect of the change in fair value of interest rate swaps, the amortization of the yield maintenance agreements and the change in the fair value of the hedged loans result in an insignificant amount of hedge ineffectiveness recognized in interest income.

Our credit exposure, if any, on interest rate swap asset positions is limited to the fair value (net of any collateral pledged to us) and interest payments of all swaps by each counterparty. Conversely, when an interest rate swap is in a liability position exceeding a certain threshold, we may be required to post collateral to the counterparty in an amount determined by the agreements. Collateral levels are monitored and adjusted on a regular basis for changes in interest rate swap values.

As of September 30, 2016, we had five interest rate swap agreements, which are scheduled to mature in June 2031, October 2031, July 2032, August 2037 and October 2037. All of our derivatives are accounted for as fair value hedges. The notional amounts of the interest rate contracts are equal to the notional amounts of the hedged loans. In September 2016, one interest rate swap scheduled to mature in August 2020 was terminated as the hedged loan was paid off. In April 2016, one interest rate swap scheduled to mature in June 2020 was terminated as the hedged loan was paid off. In both cases, prepayment fees were collected from the borrowers to settle our interest rate swap liability, resulting in no net gain or loss on the terminations of the swaps and loan pay-offs. Our interest rate swap payments are settled monthly with counterparties. Accrued interest on the swaps totaled \$15 thousand and \$28 thousand as of September 30, 2016 and December 31, 2015, respectively. Information on our derivatives follows:

	Asset derivatives	Liability derivatives	
(in thousands)	September 30, 2016	December 31, 2015	September 30, 2015
Fair value hedges:			
Interest rate contracts notional amount	\$ 4,407	\$ 19,928	\$ 22,187
Interest rate contracts fair value ¹	\$ 3	\$ 2,480	\$ 1,658
			Three months ended
(in thousands)			September 30, 2016
Increase (decrease) in value of designated interest rate swaps recognized in interest income	\$ 241	\$ (813))
Payment on interest rate swaps recorded in interest income	(132)	(231))
(Decrease) increase in value of hedged loans recognized in interest income	(268)	905)
Decrease in value of yield maintenance agreement recognized against interest income	(67)	(13))
Net loss on derivatives recognized against interest income ²	\$(226)	\$(152))
			Nine months ended
(in thousands)			September 30, 2016
Decrease in value of designated interest rate swaps recognized in interest income	\$(825)	\$(393))
Payment on interest rate swaps recorded in interest income	(445)	(700))
Increase in value of hedged loans recognized in interest income	1,022	453)
Decrease in value of yield maintenance agreement recognized against interest income	(90)	(39))
Net loss on derivatives recognized against interest income ²	\$(338)	\$(679))

¹ See Note 3 for valuation methodology.

² Includes hedge ineffectiveness loss of \$94 thousand and gain of \$79 thousand for the quarters ended September 30, 2016 and September 30, 2015, respectively. Ineffectiveness gains of \$107 thousand and \$21 thousand were recorded in interest income during the nine months ended September 30, 2016 and September 30, 2015, respectively. Changes in value of swaps were included in the assessment of hedge effectiveness. Hedge ineffectiveness is the measure of the extent to which the change in the fair value of the hedging instruments does not exactly offset the change in the fair value of the hedged items from period to period.

Our derivative transactions with counterparties are under International Swaps and Derivative Association (“ISDA”) master agreements that include “right of set-off” provisions. “Right of set-off” provisions are legally enforceable rights

Page-28

to offset recognized amounts and there may be an intention to settle such amounts on a net basis. We do not offset such financial instruments for financial reporting purposes.

Information on financial instruments that are eligible for offset in the consolidated statements of condition follows:

Offsetting of Financial Assets and Derivative Assets

(in thousands)	Gross Amounts of Recognized Assets ¹	Gross Amounts Offset in the Statements of Condition	Net Amounts Presented in the Statements of Condition ¹	Gross Amounts Not Offset in the Statements of Condition		Net Amount
				Financial Instruments	Cash Collateral Received	

September 30, 2016

Derivatives by Counterparty:

None	\$ —	\$ —	-\$ —	\$ —	\$ —	-\$ —
------	------	------	-------	------	------	-------

December 31, 2015

Derivatives by Counterparty:

Counterparty A	\$ 3	\$ —	-\$ 3	\$ (3)	\$ —	-\$ —
----------------	------	------	-------	---------	------	-------

¹ Amounts exclude accrued interest totaling zero and \$1 thousand at September 30, 2016 and December 31, 2015, respectively.

Offsetting of Financial Liabilities and Derivative Liabilities

(in thousands)	Gross Amounts of Recognized Liabilities ²	Gross Amounts Offset in the Statements of Condition	Net Amounts Presented in the Statements of Condition ²	Gross Amounts Not Offset in the Statements of Condition		Net Amount
				Financial Instruments	Cash Collateral Pledged	

September 30, 2016

Derivatives by Counterparty:

Counterparty A	\$ 2,480	\$ —	-\$ 2,480	\$ —	\$(2,480)	\$ —
----------------	----------	------	-----------	------	------------	------

December 31, 2015

Derivatives by Counterparty:

Counterparty A	\$ 1,390	\$ —	-\$ 1,390	\$(3)	\$(1,387)	\$ —
Counterparty B	268	—	268	—	(268)	—
Total	\$ 1,658	\$ —	-\$ 1,658	\$(3)	\$(1,655)	\$ —

² Amounts exclude accrued interest totaling \$15 thousand and \$27 thousand at September 30, 2016 and December 31, 2015, respectively.

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's discussion of the financial condition and results of operations, which is unaudited, should be read in conjunction with the related consolidated financial statements in this Form 10-Q and with the audited consolidated financial statements and accompanying notes included in our 2015 Annual Report on Form 10-K. Average balances, including balances used in calculating certain financial ratios, are generally comprised of average daily balances.

Forward-Looking Statements

This discussion of financial results includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, (the "1933 Act") and Section 21E of the Securities Exchange Act of 1934, as amended, (the "1934 Act"). Those sections of the 1933 Act and 1934 Act provide a "safe harbor" for forward-looking statements to encourage companies to provide prospective information about their financial performance so long as they provide meaningful, cautionary statements identifying important factors that could cause actual results to differ significantly from projected results.

Our forward-looking statements include descriptions of plans or objectives of Management for future operations, products or services, and forecasts of revenues, earnings or other measures of economic performance. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include the words "believe," "expect," "intend," "estimate" or words of similar meaning, or future or conditional verbs preceded by "will," "would," "should," "could" or "may."

Forward-looking statements are based on Management's current expectations regarding economic, legislative, and regulatory issues that may affect our earnings in future periods. A number of factors, many of which are beyond Management's control, could cause future results to vary materially from current Management expectations. Such factors include, but are not limited to, general economic conditions and the economic uncertainty in the United States and abroad, including changes in interest rates, deposit flows, real estate values, and expected future cash flows on loans and securities; integration of acquisitions and competition; changes in accounting principles, policies or guidelines; changes in legislation or regulation; adverse weather conditions, including droughts in California; and other economic, competitive, governmental, regulatory and technological factors affecting our operations, pricing, products and services.

Important factors that could cause results or performance to materially differ from those expressed in our prior forward-looking statements are detailed in Item 1A. Risk Factors section of our 2015 Form 10-K as filed with the SEC, copies of which are available from us at no charge. Forward-looking statements speak only as of the date they are made. We do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made or to reflect the occurrence of unanticipated events.

Critical Accounting Policies and Estimates

Critical accounting policies are those that are both very important to the portrayal of our financial condition and results of operations and require Management's most difficult, subjective, or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and imprecise.

Except for the Allowance for Loan Losses, as described below, there have been no material changes to our critical accounting policies, which are described in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations and Note 1 to the Consolidated Financial Statements included in our 2015 Form 10-K filed with the SEC on March 11, 2016.

Allowance for Loan Losses

The overall allowance consists of 1) specific allowances for individually identified impaired loans ("ASC 310-10") and 2) general allowances for pools of loans ("ASC 450-20"), which incorporate quantitative (e.g., loan loss rates) and qualitative risk factors (e.g., portfolio growth and trends, credit concentrations, economic and regulatory factors, etc.).

The first component, specific allowances, results from the analysis of identified problem credits and the evaluation of sources of repayment including collateral, as applicable. Through Management's ongoing loan grading and credit monitoring process, individual loans are identified that have conditions indicating the borrower may be unable to pay all amounts due in accordance with the contractual terms. These loans are evaluated for impairment individually by Management. Management considers an originated loan to be impaired when it is probable we will be unable to collect

Page-30

all amounts due according to the contractual terms of the loan agreement. When the fair value of the impaired loan is less than the recorded investment in the loan, the difference is recorded as an impairment through the establishment of a specific allowance. For loans determined to be impaired, the extent of the impairment is measured based on the present value of expected future cash flows discounted at the loan's effective interest rate at origination (for originated loans), based on the loan's observable market price, or based on the fair value of the collateral if the loan is collateral dependent or if foreclosure is imminent. Generally with problem credits that are collateral dependent, we obtain appraisals of the collateral at least annually. We may obtain appraisals more frequently if we believe the collateral value is subject to market volatility, if a specific event has occurred to the collateral, or if we believe foreclosure is imminent.

The second component is an estimate of the probable inherent losses in each loan pool with similar characteristics. This analysis encompasses the entire loan portfolio, excluding individually identified impaired loans and acquired loans whose purchase discount has not been fully accreted. Under our allowance model, loans are evaluated on a pool basis by Federal regulatory reporting codes ("CALL codes" or "segments"), which are further delineated by assigned credit risk ratings, as described in Note 5 to the Consolidated Financial Statements of this Form 10-Q. Segments include the following:

☒ Loans secured by real estate:

- 1-4 family residential construction loans
- Other construction loans and all land development and other land loans
- Secured by farmland (including residential and other improvements)
- Revolving, open-end loans secured by 1-4 family residential properties and extended under lines of credit
- Closed-end loans secured by 1-4 family residential properties, secured by first liens
- Closed-end loans secured by 1-4 family residential properties, secured by junior liens
- Secured by multifamily (5 or more) residential properties
- Loans secured by owner-occupied non-farm nonresidential properties
- Loans secured by other non-farm nonresidential properties

☒ Loans to finance agricultural production and other loans to farmers

☒ Commercial and industrial loans

☒ Loans to individuals for household, family and other personal expenditures (i.e., consumer loans)

☒ Other loans

The model determines general allowances by loan segment based on quantitative (loss history) and qualitative risk factors. Qualitative internal and external risk factors include, but are not limited to, the following:

☒ Changes in the nature and volume of the loan portfolio.

☒ Changes in the volume and severity of past due loans, the volume of non-accruals loans, and the volume and severity of adversely classified or graded loans.

☒ The existence and effect of individual loan and loan segment concentrations.

☒ Changes in lending policies and procedures, including changes in underwriting standards and collection, charge-off, and recovery practices not considered elsewhere.

☒ Changes in the experience, ability, and depth of lending management and other relevant staff.

☒ Changes in the quality of our systematic loan review processes.

☒ Changes in economic and business conditions, and developments that affect the collectability of the portfolio.

☒ Changes in the value of underlying collateral, where applicable.

☒ The effect of other external factors such as legal and regulatory requirements on the level of estimated credit losses in the portfolio.

☒ The effect of acquisitions of other loan portfolios on our infrastructure, including risk associated with entering new geographic areas as a result of such acquisitions.

¶The presence of specialized lending segments in the portfolio.

Beginning with the quarter ended March 31, 2016, Management enhanced its methodology for determining the quantitative and qualitative risk factors assigned to unimpaired loans in order to capture historical loss information at the loan level, track loss migration through risk grade deterioration, increase efficiencies related to performing the calculations, and refine how we incorporate environmental and other unique risk elements into our estimation of credit losses. The changes in methodology did not result in a material difference in general allowances. Prior to March 31, 2016, under the Bank's allowance model, each segment was assigned a quantitative loss factor that was primarily based on a rolling twenty-quarter look-back at our historical losses for that particular segment, as well as a number of other assumptions. Under the current methodology, the quantitative risk factor for each segment utilizes the greater of

Page-31

either the historical loss method based on a rolling twenty-four-quarter look-back period or migration analysis loss method based on loss history beginning March 2010.

Under the historical loss method, quarterly loss rates are calculated for each segment by dividing annualized net charge-offs during each quarter by the quarter's average segment balances. The quarterly loss rates are averaged over the entire loss history period. Under the migration analysis method, loss rates are calculated at the risk grade and segment levels by dividing the net charge-off amount by the total segment balance at the beginning of each migration period where the charged-off loan in question was present. Migration loss rates are averaged for each risk grade and segment for the entire loss history period. For each segment, the larger of the migration loss reserves or segment historical loss reserves is applied to the current loan balance. Qualitative factors are combined with these quantitative factors to arrive at the overall general allowances.

While we believe we use the best information available to determine the allowance for loan losses, our results of operations could be significantly affected if circumstances differ substantially from the assumptions used in determining the allowance. A decline in local and national economic conditions, or significant changes in other assumptions, could result in a material increase in the allowance for loan losses and may adversely affect our financial condition and results of operations. In addition, the determination of the amount of the allowance for loan losses is subject to review by bank regulators, as part of their routine examination process, which may result in the establishment of additional allowance for loan losses based upon their judgment of information available to them at the time of their examination.

For further information regarding the allowance for loan losses, see Note 5 - Loans and Allowance for Loan Losses in the Consolidated Financial Statements of this Form 10-Q.

Executive Summary

Earnings in the third quarter of 2016 totaled \$7.0 million, compared to \$4.8 million in the third quarter of 2015. Diluted earnings per share of \$1.14 in the third quarter of 2016 increased \$0.35 from \$0.79 in the same quarter a year ago, due to the recovery of a problem credit and accelerated accretion of an acquired loan discount upon early pay-off. Year-to-date earnings of \$17.4 million grew 29.1% from \$13.5 million for the same period a year ago. Diluted earnings per share were \$2.86 in the first nine months of 2016, an increase from \$2.23 for the same period in 2015.

The following are highlights of our operating and financial performance for the periods presented:

- Return on assets was 1.35% for the quarter and 1.17% for the nine months ended September 30, 2016, compared to 1.00% for the quarter and 0.97% for the nine months ended September 30, 2015. Return on equity was 12.08% for the quarter and 10.40% for the nine months ended September 30, 2016, compared to 9.00% for the quarter and 8.75% for the nine months ended September 30, 2015.

- The resolution of a problem commercial real estate credit during the third quarter added \$1.4 million in interest recoveries to net interest income and resulted in a \$1.6 million reversal of the provision for loan losses.

Credit quality remains strong with non-accrual loans totaling \$540 thousand, or 0.04% of total loans at September 30, 2016, compared to \$2.2 million, or 0.15% of total loans at December 31, 2015. Accruing loans past due 30 to 89 days totaled \$160 thousand at September 30, 2016, compared to \$2.1 million at December 31, 2015.

Loans increased by \$16.5 million and totaled \$1,467.7 million at September 30, 2016, compared to \$1,451.2 million at December 31, 2015. Year-to-date loan originations of \$129.9 million are consistent with 2015, while pay-offs of \$116.1 million are lower than the first nine months of 2015.

Deposits grew by \$73.3 million and totaled \$1,801.5 million at September 30, 2016, compared to \$1,728.2 million at December 31, 2015. Non-interest bearing deposits increased by \$90.6 million in the first nine months of 2016 and comprised 47.8% of total deposits at September 30, 2016. The cost of total deposits was 0.08% for the first nine months of 2016 compared to 0.10% during the same period in 2015.

The tax-equivalent net interest margin was 4.05% in the third quarter of 2016, compared to 3.79% in the same quarter a year ago. Net interest income totaled \$19.4 million in the third quarter of 2016, compared to \$16.9 million in the same quarter a year ago. The increase was primarily due to the \$1.4 million interest recovery previously discussed and an increase in purchased loan accretion.

Our efficiency ratio (the ratio of non-interest expense divided by the sum of net interest income and non-interest income) was 58.07% and 62.79% for the nine months ended September 30, 2016 and 2015, respectively.

All capital ratios are above regulatory requirements for a well-capitalized institution. The total risk-based capital ratio for Bancorp was 14.3% at September 30, 2016 compared to 13.4% at December 31, 2015.

Going forward:

• We have ample liquidity and capital to support both organic growth and acquisitions in the coming quarters.

• Acquisitions remain a component of our strategic plan. The Bay Area is an economically attractive area and we intend to expand our footprint through organic growth and strategic acquisitions.

• Credit quality and expense control remain key priorities.

• Our net interest margin could compress if current market interest rates do not increase.

• Although we expect the number of early pay-offs of acquired loans to decline, we cannot predict the timing and their effect on our future net interest margin.

Page-33

RESULTS OF OPERATIONS

Highlights of the financial results are presented in the following tables:

(dollars in thousands)	At September		At December	
	30,	31,	30,	31,
	2016	2015		
Selected financial condition data:				
Total assets	\$2,054,821	\$2,031,134		
Loans, net	1,451,950	1,436,229		
Deposits	1,801,469	1,728,226		
Borrowings	5,540	72,395		
Stockholders' equity	231,780	214,473		
Asset quality ratios:				
Allowance for loan losses to total loans	1.07%	1.03	%	
Allowance for loan losses to non-accrual loans	29.11	x 6.88	x	
Non-accrual loans to total loans	0.04%	0.15	%	
Capital ratios:				
Equity to total assets ratio	11.28	% 10.56	%	
Total capital (to risk-weighted assets)	14.26	% 13.37	%	
Tier 1 capital (to risk-weighted assets)	13.29	% 12.44	%	
Tier 1 capital (to average assets)	11.13	% 10.67	%	
Common equity Tier 1 capital (to risk weighted assets)	12.99	% 12.16	%	

(dollars in thousands, except per share data)	Three months ended		Nine months ended	
	September 30,	September 30,	September 30,	September 30,
	2016	2015	2016	2015
Selected operating data:				
Net interest income	\$19,381	\$ 16,883	\$55,185	\$ 49,944
Provision for loan losses	(1,550)	—	(1,550)	—
Non-interest income	2,114	2,298	6,698	7,095
Non-interest expense	11,910	11,638	35,937	35,814
Net income	6,964	4,773	17,447	13,516
Net income per common share:				
Basic	\$1.14	\$ 0.80	\$2.87	\$ 2.27
Diluted	\$1.14	\$ 0.79	\$2.86	\$ 2.23
Performance and other financial ratios:				
Return on average assets	1.35%	1.00%	1.17%	0.97%
Return on average equity	12.08%	9.00%	10.40%	8.75%
Tax-equivalent net interest margin	4.05%	3.79%	3.95%	3.88%
Efficiency ratio	55.41%	60.67%	58.07%	62.79%
Dividend payout ratio on common stock ¹	21.93%	27.50%	26.13%	29.07%

¹ Excluding the recovery of a problem credit and accelerated accretion of an acquired loan discount upon early pay-off as described herein, the dividend payout ratio would have been approximately 32% for the quarter ended September 30, 2016.

Net Interest Income

Net interest income is the difference between the interest earned on loans, investments and other interest-earning assets and the interest expense incurred on deposits and other interest-bearing liabilities. Net interest income is impacted by changes in general market interest rates and by changes in the amounts and composition of interest-earning assets and interest-bearing liabilities. Interest rate changes can create fluctuations in the net interest income due to an imbalance in the timing of repricing or maturity of assets and liabilities. We manage interest rate risk exposure with the goal of minimizing the impact of interest rate volatility on net interest income.

Net interest margin is expressed as net interest income divided by average interest-earning assets. Net interest rate spread is the difference between the average rate earned on total interest-earning assets and the average rate incurred on total interest-bearing liabilities. Both of these measures are reported on a taxable-equivalent basis. Net interest margin is the higher of the two because it reflects interest income earned on assets funded with non-interest-bearing sources of funds, such as some demand deposits and stockholders' equity.

The following table, Average Statements of Condition and Analysis of Net Interest Income, compares interest income and average interest-earning assets with interest expense and average interest-bearing liabilities for the periods presented. The table also presents net interest income, net interest margin and net interest rate spread for each period reported.

Average Statements of Condition and Analysis of Net Interest Income

	Three months ended September 30, 2016			Three months ended September 30, 2015		
	Average Balance	Interest Income/ Expense	Yield/ Rate	Average Balance	Interest Income/ Expense	Yield/ Rate
(dollars in thousands)						
Assets						
Interest-bearing due from banks ¹	\$79,672	\$105	0.51 %	\$51,378	\$35	0.27 %
Investment securities ^{2, 3}	394,980	2,120	2.15 %	389,260	2,094	2.15 %
Loans ^{1, 3, 4}	1,454,617	18,182	4.89 %	1,352,023	15,800	4.57 %
Total interest-earning assets ¹	1,929,269	20,407	4.14 %	1,792,661	17,929	3.91 %
Cash and non-interest-bearing due from banks	48,901			43,054		
Bank premises and equipment, net	8,808			9,680		
Interest receivable and other assets, net	61,649			57,589		
Total assets	\$2,048,627			\$1,902,984		
Liabilities and Stockholders' Equity						
Interest-bearing transaction accounts	\$91,035	\$27	0.12 %	\$93,933	\$28	0.12 %
Savings accounts	152,370	15	0.04 %	135,202	13	0.04 %
Money market accounts	531,130	112	0.08 %	506,952	125	0.10 %
Time accounts including CDARS	160,595	190	0.47 %	157,252	212	0.53 %
Overnight borrowings ¹	—	—	— %	188	—	— %
FHLB fixed-rate advances ¹	—	—	— %	15,000	79	2.07 %
Subordinated debentures ¹	5,516	109	7.68 %	5,316	105	7.73 %
Total interest-bearing liabilities	940,646	453	0.19 %	913,843	562	0.24 %
Demand accounts	864,460			765,284		
Interest payable and other liabilities	14,124			13,467		
Stockholders' equity	229,397			210,390		
Total liabilities & stockholders' equity	\$2,048,627			\$1,902,984		
Tax-equivalent net interest income/margin ¹		\$19,954	4.05 %		\$17,367	3.79 %
Reported net interest income/margin ¹		\$19,382	3.93 %		\$16,883	3.69 %

Explanation of Responses:

Tax-equivalent net interest rate spread	3.95%	3.67%
---	-------	-------

Page-35

Edgar Filing: Theravance Biopharma, Inc. - Form 4

(dollars in thousands)	Nine months ended September 30, 2016			Nine months ended September 30, 2015		
	Average Balance	Interest Income/ Yield/ ExpenseRate	Yield/ ExpenseRate	Average Balance	Interest Income/ Yield/ ExpenseRate	Yield/ ExpenseRate
Assets						
Interest-bearing due from banks ¹	\$39,293	\$155	0.52 %	\$55,509	\$107	0.25 %
Investment securities ^{2, 3}	403,986	6,458	2.13 %	340,373	5,864	2.30 %
Loans ^{1, 3, 4}	1,446,053	52,072	4.73 %	1,346,689	47,063	4.61 %
Total interest-earning assets ¹	1,889,332	58,685	4.08 %	1,742,571	53,034	4.01 %
Cash and non-interest-bearing due from banks	39,788			44,368		
Bank premises and equipment, net	8,926			9,786		
Interest receivable and other assets, net	60,022			58,153		
Total assets	\$1,998,068			\$1,854,878		
Liabilities and Stockholders' Equity						
Interest-bearing transaction accounts	\$95,112	\$82	0.11 %	\$93,762	\$88	0.13 %
Savings accounts	148,050	43	0.04 %	133,553	38	0.04 %
Money market accounts	523,641	330	0.08 %	494,142	375	0.10 %
Time accounts including CDARS	160,523	579	0.48 %	156,458	648	0.55 %
Overnight borrowings ¹	7,190	22	0.42 %	194	—	— %
FHLB fixed-rate advances ¹	9,087	456	6.59 %	15,000	236	2.07 %
Subordinated debentures ¹	5,469	325	7.80 %	5,261	314	7.98 %
Total interest-bearing liabilities	949,072	1,837	0.26 %	898,370	1,699	0.25 %
Demand accounts	810,190			735,487		
Interest payable and other liabilities	14,651			14,466		
Stockholders' equity	224,155			206,555		
Total liabilities & stockholders' equity	\$1,998,068			\$1,854,878		
Tax-equivalent net interest income/margin ¹		\$56,848	3.95 %		\$51,335	3.88 %
Reported net interest income/margin ¹		\$55,185	3.84 %		\$49,944	3.78 %
Tax-equivalent net interest rate spread			3.82 %			3.76 %

¹ Interest income/expense is divided by actual number of days in the period times 360 days to correspond to stated interest rate terms, where applicable.

² Yields on available-for-sale securities are calculated based on amortized cost balances rather than fair value, as changes in fair value are reflected as a component of stockholders' equity. Investment security interest is earned on 30/360 day basis monthly.

³ Yields and interest income on tax-exempt securities and loans are presented on a taxable-equivalent basis using the Federal statutory rate of 35 percent.

⁴ Average balances on loans outstanding include non-performing loans. The amortized portion of net loan origination fees is included in interest income on loans, representing an adjustment to the yield.

Third Quarter of 2016 Compared to Third Quarter of 2015

Net interest income totaled \$19.4 million in the third quarter of 2016, compared to \$16.9 million in the same quarter a year ago. The tax-equivalent net interest margin was 4.05% in the third quarter of 2016, compared to 3.79% in the same quarter in the previous year. The \$2.5 million increase in net interest income was primarily due to an increase in average interest-earning assets of \$136.6 million, or 7.6%, compared to the same period in 2015. The increase was comprised of a \$102.6 million increase in average loans, a \$28.3 million increase in average interest-bearing due from banks, and a \$5.7 million increase in average securities. Additional positive variances in both net interest income and

margin in the third quarter of 2016 included the \$1.4 million interest recovery previously discussed and an increase in purchased loan accretion as shown in the table below, partially offset by a decline in the average yields on our loan portfolio. In addition, interest expense was lower as a result of the Federal Home Loan Bank fixed rate advance prepayment in 2016.

First Nine Months of 2016 Compared to First Nine Months of 2015

Net interest income totaled \$55.2 million in the first nine months of 2016 compared to \$49.9 million for the same period in 2015. The tax-equivalent net interest margin was 3.95% in the first nine months of 2016, compared to 3.88% in the same period in the previous year. The \$5.3 million increase in net interest income was primarily due to an increase in average interest-earning assets of \$146.8 million, or 8.4%, compared to the same period in 2015. The increase was comprised of a \$99.4 million increase in average loans and a \$63.6 million increase in average securities, partially offset by a \$16.2 million decrease in average interest-bearing due from banks. Additional positive variances in both net interest income and margin in 2016 included the interest recovery of \$1.4 million mentioned above and a \$696 thousand increase in gains on payoffs of PCI loans as shown in the table below, which were partially offset by lower average yields on loans and investments and prepayment fees of \$312 thousand on a Federal Home Loan Bank advance in the second quarter of 2016.

Market interest rates are, in part, based on the target federal funds interest rate (the interest rate banks charge each other for short-term borrowings) implemented by the Federal Reserve Open Market Committee ("FOMC"). In December 2015, the FOMC raised the target federal funds rate by 25 basis points to a range of 0.25% to 0.50% from the historic low of 0.00% to 0.25% that had not changed during the previous seven years. The prolonged low interest rate environment, especially the low long-term interest rates, has resulted in downward pricing pressure on our interest-earning assets. We have experienced significant net interest margin compression over the last several years and our net interest margin in the future may compress if current market interest rates do not increase.

Early pay-offs or prepayments of our acquired loans with significant unamortized purchase discount/premium could result in volatility in our net interest margin and cannot be predicted. As our acquired loans continue to pay off, we expect the accretion on acquired loans to continue to decline. Accretion and gains on pay-offs of purchased loans recorded to interest income were as follows:

	Three months ended		Nine months ended		September 30, 2015	Basis point impact to net interest margin
	September 30, 2016	September 30, 2015	September 30, 2016	September 30, 2015		
(dollars in thousands)	Dollar Amount	Basis point impact to net interest margin	Dollar Amount	Basis point impact to net interest margin	Dollar Amount	Basis point impact to net interest margin
Accretion on PCI loans	\$ 89	2 bps	\$ 128	3 bps	\$ 274	2 bps
Accretion on non-PCI loans	\$ 605	12 bps	\$ 366	8 bps	\$ 1,252	9 bps
Gains on pay-offs of PCI loans	\$ —	0 bps	\$ 1	0 bps	\$ 740	5 bps
					\$ 44	0 bps

Provision for Loan Losses

Management assesses the adequacy of the allowance for loan losses on a quarterly basis based on several factors including growth of the loan portfolio, analysis of probable losses in the portfolio, historical loss experience and the current economic climate. Actual losses on loans are charged against the allowance, and the allowance is increased by loss recoveries and provisions for loan losses charged to expense.

A \$1.6 million reversal of the provision for loan losses was recorded in the third quarter of 2016 and resulted from the charged-off principal recovery of \$2.2 million on the problem credit previously mentioned. No provision for loan losses was recorded in the same quarter a year ago. Net recoveries in the third quarter of 2016 totaled \$2,176 thousand, compared to \$102 thousand in the same quarter a year ago.

As described above, a \$1.6 million reversal of the loan loss provision was recorded in the first nine months of 2016, compared to no provision for loan losses recognized in the first nine months of 2015. Net recoveries were \$2,264 thousand in the first nine months of 2016, compared to net charge-offs of \$643 thousand in the first nine months of 2015. A protracted problem land development loan was sold in the second quarter of 2015 resulting in an \$839 thousand charge-off.

The ratio of loan loss reserves to total loans was 1.07% at September 30, 2016, compared to 1.03% at December 31, 2015. Non-accrual loans totaled \$540 thousand, or 0.04% of total loans at September 30, 2016, compared to \$2.2 million, or 0.15% at December 31, 2015.

Impaired loan balances totaled \$19.7 million at September 30, 2016, compared to \$21.2 million at December 31, 2015, with specific valuation allowances of \$1.3 million and \$1.2 million for the same respective dates. The decrease in impaired loan balances primarily relates to the pay-off of a problem credit totaling \$1.9 million as of December 31, 2015 and the pay-off/pay-down of three commercial loans, partially offset by the addition of a performing commercial real estate loan modified in a troubled debt restructuring. Classified assets (loans with substandard or doubtful risk grades) increased to \$22.6 million at September 30, 2016, from \$22.3 million at December 31, 2015. There were no loans with doubtful risk grades at September 30, 2016 or December 31, 2015.

Non-interest Income

The table below details the components of non-interest income.

(dollars in thousands)	Three months ended		Amount Increase (Decrease)	Percent Increase (Decrease)
	September 2016	September 30, 2015		
Service charges on deposit accounts	\$447	\$ 489	\$ (42)	(8.6)%
Wealth Management and Trust Services	506	568	(62)	(10.9)%
Debit card interchange fees	393	372	21	5.6 %
Merchant interchange fees	114	171	(57)	(33.3)%
Earnings on bank-owned life insurance	216	204	12	5.9 %
Dividends on FHLB stock	223	209	14	6.7 %
Gains on investment securities, net	—	72	(72)	NM
Other income	215	213	2	0.9 %
Total non-interest income	\$2,114	\$ 2,298	\$ (184)	(8.0)%

(dollars in thousands)	Nine months ended		Amount Increase (Decrease)	Percent Increase (Decrease)
	September 30, 2016	September 30, 2015		
Service charges on deposit accounts	\$1,344	\$ 1,518	\$ (174)	(11.5)%
Wealth Management and Trust Services	1,599	1,809	(210)	(11.6)%
Debit card interchange fees	1,112	1,087	25	2.3 %
Merchant interchange fees	355	430	(75)	(17.4)%
Earnings on bank-owned life insurance	626	610	16	2.6 %
Dividends on FHLB stock	577	817	(240)	(29.4)%
Gains on investment securities, net	394	80	314	392.5 %
Other income	691	744	(53)	(7.1)%
Total non-interest income	\$6,698	\$ 7,095	\$ (397)	(5.6)%

NM - Not Meaningful

Third Quarter of 2016 Compared to Third Quarter of 2015

Non-interest income decreased by \$184 thousand in the third quarter of 2016 to \$2.1 million, compared to \$2.3 million in the same quarter a year ago. The decrease was partially due to a \$72 thousand gain on the sale of four securities in the third quarter of 2015, lower merchant card interchange fees of \$57 thousand related to a decline in sales volume and \$62 thousand lower wealth management and trust services fees in the third quarter of 2016.

First Nine Months of 2016 Compared to First Nine Months of 2015

Explanation of Responses:

Non-interest income decreased by \$397 thousand to \$6.7 million for the first nine months of 2016, compared to \$7.1 million for the first nine months of 2015. The decrease resulted from lower dividends on FHLB stock, lower wealth management-related fees, and lower service charges on business analysis accounts due to higher average deposit balances, partially offset by higher gains on the sale of investment securities.

Non-interest Expense

The table below details the components of non-interest expense.

(dollars in thousands)	Three months ended		Amount Increase (Decrease)	Percent Increase (Decrease)	
	September 30, 2016	September 30, 2015			
Salaries and related benefits	\$6,683	\$ 6,300	\$ 383	6.1	%
Occupancy and equipment	1,275	1,346	(71)	(5.3)%
Depreciation and amortization	449	441	8	1.8	%
Federal Deposit Insurance Corporation insurance	253	250	3	1.2	%
Data processing	894	835	59	7.1	%
Professional services	476	493	(17)	(3.4)%
Directors' expense	143	182	(39)	(21.4)%
Information technology	307	186	121	65.1	%
Provision for losses on off-balance sheet commitments	—	324	(324)	NM	
Other non-interest expense					
Advertising	177	75	102	136.0	%
Other expense	1,253	1,206	47	3.9	%
Total other non-interest expense	1,430	1,281	149	11.6	%
Total non-interest expense	\$11,910	\$ 11,638	\$ 272	2.3	%

(dollars in thousands)	Nine months ended		Amount Increase (Decrease)	Percent Increase (Decrease)	
	September 30, 2016	September 30, 2015			
Salaries and related benefits	\$20,155	\$ 19,762	\$ 393	2.0	%
Occupancy and equipment	3,731	4,181	(450)	(10.8)%
Depreciation and amortization	1,343	1,512	(169)	(11.2)%
Federal Deposit Insurance Corporation insurance	760	739	21	2.8	%
Data processing	2,666	2,413	253	10.5	%
Professional services	1,528	1,572	(44)	(2.8)%
Directors' expense	448	620	(172)	(27.7)%
Information technology	665	554	111	20.0	%
Provision for losses on off-balance sheet commitments	150	14	136	NM	
Other non-interest expense					
Advertising	378	197	181	91.9	%
Other expense	4,113	4,250	(137)	(3.2)%
Total other non-interest expense	4,491	4,447	44	1.0	%
Total non-interest expense	\$35,937	\$ 35,814	\$ 123	0.3	%

NM - Not Meaningful

Third Quarter of 2016 Compared to Third Quarter of 2015

Non-interest expense increased by \$272 thousand to \$11.9 million in the third quarter of 2016, compared to \$11.6 million in the same quarter a year ago. The increase was partially due to an increase in salaries and benefits related to annual merit increases and higher full time equivalents in 2016, and increases in information technology improvement costs and advertising. The increases in expenses were partially offset by no provision for off-balance sheet commitments recorded in the third quarter of 2016 compared to \$324 thousand in the same quarter last year.

First Nine Months of 2016 Compared to First Nine Months of 2015

Non-interest expense increased by \$123 thousand to \$35.9 million for the first nine months of 2016, compared to \$35.8 million for the first nine months of 2015. The increase resulted from the same reasons described above and higher expenses related to provision for off-balance sheet commitments, and data processing costs. These increases were partially offset by a decrease in occupancy and equipment expenses related to the relocation of offices in 2016, and lease accounting adjustments recorded in the first nine months of 2015.

Provision for Income Taxes

The provision for income taxes for the third quarter of 2016 totaled \$4.2 million at an effective tax rate of 37.5%, compared to \$2.8 million at an effective tax rate of 36.7% in the same quarter last year. The provision for income taxes for the first nine months of 2016 totaled \$10.0 million at an effective tax rate of 36.5%, compared to \$7.7 million at an effective tax rate of 36.3% for the first nine months of 2015. These provisions reflect accruals for taxes at the applicable rates for federal income tax and California franchise tax based upon reported pre-tax income, and adjusted for the effects of all permanent differences between income for tax and financial reporting purposes (such as earnings on tax exempt loans and municipal securities, BOLI, and low income housing tax credits). We forecast annual pre-tax income and these permanent differences to project our effective tax rates. As a result, there are fluctuations in the effective rate from period to period based on the relationship of net permanent differences to income before tax.

We file a consolidated return in the U.S. Federal tax jurisdiction and a combined return in the State of California tax jurisdiction. There were no ongoing federal or state income tax examinations at the issuance of this report. At September 30, 2016, neither the Bank nor Bancorp had accruals for interest or penalties related to unrecognized tax benefits.

FINANCIAL CONDITION SUMMARY

Investment Securities

The investment securities portfolio totaled \$425.4 million at September 30, 2016, a \$62.0 million decrease from December 31, 2015. Year-to-date investment security purchases totaling \$140.9 million were offset by paydowns and maturities totaling \$136.1 million and sales totaling \$68.7 million. The sales proceeds were used to pay down our borrowings and resulted in net gains of \$393.9 thousand.

Investment securities in our portfolio that may be backed by mortgages having sub-prime or Alt-A features (certain privately issued CMOs) represent 0.1% and 0.2% of our total investment portfolio at September 30, 2016 and December 31, 2015, respectively.

The table below summarizes our investment in obligations of state and political subdivisions at September 30, 2016 and December 31, 2015.

(dollars in thousands)	September 30, 2016			December 31, 2015		
	Amortized Cost	Fair Value	% of Total State and Political Subdivisions	Amortized Cost	Fair Value	% of Total State and Political Subdivisions
Within California:						
General obligation bonds	\$15,252	\$15,574	13.7 %	\$18,642	\$18,830	18.6 %
Revenue bonds	10,942	11,307	9.7	15,453	15,767	15.5

Explanation of Responses:

Edgar Filing: Theravance Biopharma, Inc. - Form 4

Tax allocation bonds	4,632	4,829	4.2		5,411	5,603	5.4
Total within California	30,826	31,710	27.6		39,506	40,200	39.5
Outside California:							
General obligation bonds	72,228	73,647	64.8		51,920	52,990	51.9
Revenue bonds	8,430	8,538	7.6		8,603	8,629	8.6
Total outside California	80,658	82,185	72.4		60,523	61,619	60.5
Total obligations of state and political subdivisions	\$ 111,484	\$ 113,895	100.0	%	\$ 100,029	\$ 101,819	100.0 %

Page-40

The portion of the portfolio outside the state of California is distributed among twenty states. The largest concentrations are in Washington (11.8%), Minnesota (11.7%), and Texas (11.3%). Revenue bonds, both within and outside California, primarily consisted of bonds relating to essential services (such as public improvements and utilities) and school district bonds.

Investments in states, municipalities and political subdivisions are subject to an initial pre-purchase credit assessment and ongoing monitoring. Key considerations include:

- The soundness of a municipality's budgetary position and stability of its tax revenues
- Debt profile and level of unfunded liabilities, diversity of revenue sources, taxing authority of the issuer
- Local demographics/economics including unemployment data, largest taxpayers and local employers, income indices and home values
- For revenue bonds, the source and strength of revenue for municipal authorities including the obligor's financial condition and reserve levels, annual debt service and debt coverage ratio, and credit enhancement (such as insurer's strength)
- Credit ratings by major credit rating agencies

Loans

Loans totaled \$1,467.7 million at September 30, 2016, an increase of \$16.5 million from \$1,451.2 million at December 31, 2015. New loan volume in the first nine months of 2016 of \$129.9 million were primarily in investor commercial real estate, commercial and industrial and owner-occupied commercial real estate and were spread throughout our markets. Advances on new and existing construction loans during 2016 totaled \$31.0 million, partially offset by pay-offs of \$14.2 million. Total pay-offs of \$116.1 million, combined with scheduled payments and advances on existing loan commitments, produced the net increase from December 31, 2015. Two investor commercial real estate loans totaling \$22 million accounted for 20% of the pay-offs. One of these loans was a \$13 million credit for which the Bank chose not to match a competitor's highly aggressive loan terms as they were not consistent with our credit policy or lending appetite. The remaining \$9 million loan was a planned pay-off, which facilitated new financing on a related property. We believe our loan pipeline is robust, reflecting growth prospects across our markets.

Liabilities

During the first nine months of 2016, total liabilities increased by \$6.4 million to \$1,823.0 million. Deposits totaled \$1,801.5 million at September 30, 2016, compared to \$1,728.2 million at December 31, 2015. The \$73.3 million increase was primarily due to new customer relationships and normal business activity for existing commercial customers. The third quarter of 2016 included some higher than usual deposit increases from a few of our largest business customers due to the nature of their businesses, which could decline during the fourth quarter. Non-interest bearing deposits totaled \$860.6 million, or 47.8% of total deposits at September 30, 2016, compared to 44.6% at December 31, 2015. FHLB and other borrowings also declined \$67.0 million. We retired a \$15 million fixed rate FHLB advance in the second quarter to reduce our cost of funds going forward and there were no overnight borrowings at September 30, 2016.

Capital Adequacy

We are subject to various regulatory capital requirements administered by the federal banking agencies. Failure to meet minimum capital requirements can initiate certain mandatory and possibly additional discretionary actions by regulators that, if undertaken, could have a material effect on our consolidated financial statements. Under capital

adequacy guidelines and the regulatory framework for prompt corrective action, we must meet specific capital guidelines that involve quantitative measures of our assets, liabilities, and certain off-balance sheet items as calculated under regulatory accounting practices. The capital amounts and the Bank's prompt corrective action classification are also subject to qualitative judgments by the regulators about components of capital, risk weightings and other factors.

Quantitative measures established by regulation to ensure capital adequacy require Bancorp and the Bank to maintain minimum amounts and ratios (set forth in the table below) of total and Tier 1 capital to risk-weighted assets and of Tier 1 capital to quarterly average assets.

Capital ratios are reviewed by Management on a regular basis to ensure that capital exceeds the prescribed regulatory minimums and is adequate to meet our anticipated future needs. For all periods presented, the Bank's ratios exceed

Page-41

the regulatory definition of “well capitalized” under the regulatory framework for prompt corrective action and Bancorp’s ratios exceed the required minimum ratios for capital adequacy purposes.

In July 2013, the Board of Governors of the Federal Reserve, the FDIC and the Office of the Comptroller of the Currency, finalized regulatory capital rules known as "Basel III". The rules became effective beginning January 2015, and will be phased-in and become fully implemented by January 2019. The guidelines, among other things, changed the minimum capital requirements of bank holding companies, by increasing the Tier 1 capital to risk-weighted assets ratio to 6%, and introducing a new requirement to maintain a minimum ratio of common equity Tier 1 capital to risk-weighted assets of 4.5%. By 2019, when fully phased in, the rules will require further increases to certain minimum capital requirements and a capital conservation buffer of an additional 2.5% of risk-weighted assets. Basel III permits certain banks such as us to exclude accumulated other comprehensive income or loss from regulatory capital through a one-time election in the first quarter of 2015. As it was consistent with our existing treatment, there were no changes to our capital ratios as a result of making this election. The changes that affected us most significantly include:

- shifting off-balance sheet items with an original maturity of one year or less from 0% to 20% risk weight,
- moving past due loan balances from 100% to 150% risk weight,
- deducting deferred tax assets associated with NOLs and tax credits from common equity Tier 1 capital, and
- subjecting deferred tax assets related to temporary timing differences that exceed certain thresholds to 250% risk-weighting, beginning in 2018.

We have modeled our ratios under the fully phased-in Basel III rules and, based on present facts, we do not expect that we will be required to raise additional capital as a result of the fully phased-in rules.

To be categorized as well capitalized the Bank must maintain minimum total risk-based, Tier 1 risk-based, Tier 1 leverage, and common equity Tier 1 ratios as set forth in the second table below. The most recent notification from the FDIC categorized the Bank as well capitalized under the regulatory framework for prompt corrective action as of June 30, 2016. There are no conditions or events since that notification that Management believes have changed the Bank’s categories, and we expect the Bank to remain well capitalized for prompt corrective action purposes.

The Bancorp’s and Bank’s capital adequacy ratios as of September 30, 2016 and December 31, 2015 are presented in the following tables. Bancorp's Tier 1 capital includes the subordinated debentures, which are not included at the Bank level. We continued to build capital in 2016 through the accumulation of net income.

Capital Ratios for Bancorp (dollars in thousands)	Actual Ratio		Adequately Capitalized Threshold ¹	
	Amount	Ratio	Amount	Ratio
September 30, 2016				
Total Capital (to risk-weighted assets)	\$243,126	14.26%	\$147,048	8.625%
Tier 1 Capital (to risk-weighted assets)	\$226,513	13.29%	\$112,948	6.625%
Tier 1 Capital (to average assets)	\$226,513	11.13%	\$81,413	4.000%
Common Equity Tier 1 (to risk-weighted assets)	\$221,373	12.99%	\$87,372	5.125%
December 31, 2015				
Total Capital (to risk-weighted assets)	\$227,269	13.37%	\$135,996	8.00%
Tier 1 Capital (to risk-weighted assets)	\$211,521	12.44%	\$101,992	6.00%
Tier 1 Capital (to average assets)	\$211,521	10.67%	\$79,296	4.00%
Common Equity Tier 1 (to risk-weighted assets)	\$206,724	12.16%	\$76,498	4.50%

¹ The 2016 adequately capitalized threshold includes the capital conservation buffer that was effective January 1, 2016. These ratios are not reflected on a fully phased-in basis, which will occur in January 2019.

Capital Ratios for the Bank (dollars in thousands)	Actual Ratio		Adequately Capitalized Threshold ¹		Ratio to be Well Capitalized under Prompt Corrective Action Provisions	
	Amount	Ratio	Amount	Ratio	Amount	Ratio
September 30, 2016						
Total Capital (to risk-weighted assets)	\$237,345	13.92%	\$147,018	8.625%	\$170,448	10.00%
Tier 1 Capital (to risk-weighted assets)	\$220,733	12.95%	\$112,928	6.625%	\$136,358	8.00%
Tier 1 Capital (to average assets)	\$220,733	10.85%	\$81,398	4.000%	\$101,748	5.00%
Common Equity Tier 1 (to risk-weighted assets)	\$220,733	12.95%	\$87,358	5.125%	\$110,798	6.50%
December 31, 2015						
Total Capital (to risk-weighted assets)	\$222,830	13.11%	\$135,968	8.00%	\$169,968	10.00%
Tier 1 Capital (to risk-weighted assets)	\$207,082	12.18%	\$101,978	6.00%	\$135,968	8.00%
Tier 1 Capital (to average assets)	\$207,082	10.45%	\$79,268	4.00%	\$99,088	5.00%
Common Equity Tier 1 (to risk-weighted assets)	\$207,082	12.18%	\$76,488	4.50%	\$110,478	6.50%

¹ The 2016 adequately capitalized threshold includes the capital conservation buffer that was effective January 1, 2016. These ratios are not reflected on a fully phased-in basis, which will occur in January 2019.

Liquidity

The goal of liquidity management is to provide adequate funds to meet loan demand and fund operating activities and deposit withdrawals. We accomplish this goal by maintaining an appropriate level of liquid assets and formal lines of credit with the FHLB, FRBSF and correspondent banks that enable us to borrow funds as needed. Our Asset Liability Management Committee ("ALCO"), which is comprised of certain directors of the Bank, is responsible for approving and monitoring our liquidity targets and strategies. ALCO has adopted a contingency funding plan that provides early detection of a potential shortfall in liquidity below internal requirements and institutes prompt responses that may prevent or alleviate a potential liquidity crisis.

We obtain funds from the repayment and maturity of loans as well as deposit inflows, investment security maturities and paydowns, federal funds purchases, FHLB advances, and other borrowings. Our primary uses of funds are the origination of loans, the purchase of investment securities, withdrawals of deposits, maturity of certificates of deposit, repayment of borrowings and dividends to common stockholders.

The most volatile factor in our short-term liquidity position has been the level of customer deposits. We attract and retain new deposits, which depends upon the variety and effectiveness of our customer account products, service and convenience, and rates paid to customers, as well as our financial strength. However, the business model and cyclical nature of the cash cycles of some of our large commercial depositors may also cause short-term volatility in their deposit balances held with us.

Any long-term decline in deposit funding would adversely affect our liquidity. Management monitors our liquidity position daily and regularly adjusts our investments in liquid assets based upon our assessment of expected loan demand and pay-off activities, expected deposit flows, desired mix and yields on interest-earning assets, and the objectives of our asset/liability management program. In addition, we have secured borrowing capacity through the FHLB and FRBSF, as discussed in Note 6 to the consolidated financial statements, that can be drawn upon. Management anticipates our current strong liquidity position and core deposit base will provide adequate liquidity to fund our operations.

At September 30, 2016 our liquid assets, which included unencumbered available-for-sale securities and cash, totaled \$393.1 million, an increase of \$18.1 million from December 31, 2015. As presented in the accompanying unaudited

consolidated statements of cash flows, the sources of liquidity vary between periods. Our cash and cash equivalents at September 30, 2016 totaled \$96.9 million, an increase of \$70.6 million from December 31, 2015. The primary sources of funds during the first nine months of 2016 included an increase in net deposits of \$73.2 million, \$63.9 million in proceeds from sales, pay-downs and maturities of investment securities, net of purchases and \$20.3 million net cash provided by operating activities. The primary uses of liquidity during the first nine months of 2016 were the repayment of \$67.0 million in borrowings to lower our funding costs going forward and loan principal collections (net of loan originations) of \$11.7 million.

Undrawn credit commitments, as discussed in Note 8 to the consolidated financial statements, totaled \$416.5 million at September 30, 2016. These commitments, to the extent used, are expected to be funded primarily through the

Page-43

repayment of existing loans, deposit growth and liquid assets. Over the next twelve months, \$111.9 million of time deposits will mature. We expect these funds to be replaced with new deposits. Our emphasis on local deposits combined with our well capitalized equity position, provides a very stable funding base.

Since Bancorp is a holding company and does not conduct regular banking operations, its primary sources of liquidity are dividends from the Bank. Under the California Financial Code, payment of a dividend from the Bank to Bancorp without advance regulatory approval is restricted to the lesser of the Bank's retained earnings or the amount of the Bank's net profits from the previous three fiscal years less the amount of dividends paid during that period. The primary uses of funds for Bancorp are shareholder dividends and ordinary operating expenses. Bancorp held \$5.4 million of cash at September 30, 2016. Bancorp obtained dividend distributions from the Bank in the amount of \$6.4 million in the first nine months of 2016. These funds are deemed sufficient to cover Bancorp's operational needs and cash dividends to shareholders through the end of 2016. Management anticipates that there will be sufficient earnings at the Bank to provide dividends to Bancorp to meet its funding requirements for the foreseeable future.

ITEM 3. Quantitative and Qualitative Disclosure about Market Risk

Market risk is defined as the risk of loss arising from an adverse change in the market value (or prices) of financial instruments. A significant form of market risk is interest rate risk, which is inherent in our investment, borrowing, lending and deposit gathering activities. The Bank manages interest rate sensitivity to minimize the exposure of our net interest margin, earnings, and capital to changes in interest rates. Interest rate changes can create fluctuations in the net interest margin due to an imbalance in the timing of repricing or maturity of assets or liabilities.

To mitigate interest rate risk, the structure of the Consolidated Statement of Condition is managed with the objective of correlating the effects of interest rate changes on loans and investments with those of deposits and borrowings. The asset liability management policy sets limits on the acceptable amount of change to net interest income and economic value of equity in different interest rate environments.

From time to time, we enter into interest rate swap contracts to mitigate the changes in the fair value of specified long-term fixed-rate loans and firm commitments to enter into long-term fixed-rate loans caused by changes in interest rates. See Note 9 to the Consolidated Financial Statements in this Form 10-Q.

Exposure to interest rate risk is reviewed at least quarterly by ALCO and the Board of Directors. Simulation models are used to measure interest rate risk and to evaluate strategies to improve profitability. A simplified statement of condition is prepared on a quarterly basis as a starting point, using instrument level data of our actual loans, investments, borrowings and deposits as inputs. If potential changes to net equity value and net interest income resulting from hypothetical interest rate changes are not within the limits established by the Board of Directors, Management may adjust the asset and liability mix to bring the risk position within approved limits.

In December 2015, the FOMC raised the target federal funds rate by 25 basis points to a range of 0.25% to 0.50%, from the historic low of 0.00% to 0.25%, which had been maintained since December 2008. The Bank currently has low interest rate risk. Net interest margin is expected to increase after interest rates go up, but there may be a lag between repricing of certain floating rate loans at their floors and increases in rates.

Based on our most recent simulation, net interest income is projected to increase by approximately 2% in year one given an immediate 200 basis point increase in interest rates and increase by approximately 8% in year two. The interest rate risk is within policy guidelines established by ALCO and the Board of Directors.

ITEM 4. Controls and Procedures

Bank of Marin Bancorp and its subsidiary (the "Company") conducted an evaluation under the supervision and with the participation of our Management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act of 1934 (the "Act")) as of the end of the period covered by this report. The term disclosure controls and procedures means controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Act is accumulated and communicated to our Management, including our principal executive and principal financial officers, or persons performing similar

Page-44

functions, as appropriate to allow timely decisions regarding required disclosure. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

During the last fiscal quarter there were no significant changes that materially affected, or are reasonably likely to affect, our internal control over financial reporting.

PART II OTHER INFORMATION

ITEM 1 Legal Proceedings

We may be party to legal actions which arise from time to time as part of the normal course of our business. We believe, after consultation with legal counsel, that we have meritorious defenses in these actions, and that litigation contingency liability, if any, will not have a material adverse effect on our financial position, results of operations, or cash flows.

We are responsible for our proportionate share of certain litigation indemnifications provided to Visa U.S.A. by its member banks in connection with lawsuits related to anti-trust charges and interchange fees. For further details, see Note 13 to the Consolidated Financial Statements in Item 8 of our 2015 Form 10-K and Note 8 to the Consolidated Financial Statements in this Form 10-Q herein.

ITEM 1A Risk Factors

There have been no material changes from the risk factors previously disclosed in our 2015 Form 10-K. Refer to “Risk Factors” in Item 1A of our 2015 Form 10-K, pages 11 through 20.

ITEM 2 Unregistered Sales of Equity Securities and Use of Proceeds

We did not have any unregistered sales or repurchases of our equity securities during the three months ended September 30, 2016.

ITEM 3 Defaults Upon Senior Securities

None.

ITEM 4 Mine Safety Disclosures

Not applicable.

ITEM 5 Other Information

None.

ITEM 6 Exhibits

The following exhibits are filed as part of this report or hereby incorporated by references to filings previously made with the SEC.

Exhibit Number	Exhibit Description	Incorporated by Reference			
		Form	File No.	Exhibit	Filing Date Herewith
2.01	Modified Whole Bank Purchase and Assumption Agreement dated February 18, 2011 among Federal Deposit Insurance Corporation, Receiver of Charter Oak Bank, Napa, California, Federal Deposit Insurance Corporation, and Bank of Marin	8-K	001-33572	99.2	February 28, 2011
2.02	Agreement and Plan of Merger with NorCal Community Bancorp, dated July 1, 2013	8-K	001-33572	2.1	July 5, 2013
3.01	Articles of Incorporation, as amended	10-Q	001-33572	3.01	November 7, 2007
3.02	Bylaws	10-Q	001-33572	3.02	May 9, 2011
3.02a	Bylaw Amendment	8-K	001-33572	3.03	July 6, 2015
4.01	Rights Agreement dated as of July 2, 2007	8-A12B	001-33572	4.1	July 2, 2007
4.01a	Rights Agreement, Amendment No. 1, dated June 17, 2016	8-K	001-33572	4.2	June 22, 2016
10.01	2007 Employee Stock Purchase Plan	S-8	333-144810	4.1	July 24, 2007
10.02	1989 Stock Option Plan	S-8	333-144807	4.1	July 24, 2007
10.03	1999 Stock Option Plan	S-8	333-144808	4.1	July 24, 2007
10.04	2007 Equity Plan	S-8	333-144809	4.1	July 24, 2007
10.05	2010 Director Stock Plan	S-8	333-167639	4.1	June 21, 2010
10.06	Form of Indemnification Agreement for Directors and Executive Officers dated August 9, 2007	10-Q	001-33572	10.06	November 7, 2007
10.07	Form of Employment Agreement dated January 23, 2009	8-K	001-33572	10.1	January 26, 2009
10.08	Intentionally left blank				
10.09	2010 Annual Individual Incentive Compensation Plan	8-K	001-33572	99.1	October 21, 2010
10.10a	Salary Continuation Agreements with executive officers, Russell Colombo, Chief Executive Officer and Peter Pelham, Director of Retail Banking, dated January 1, 2011	8-K	001-33572	10.1 10.4	January 6, 2011
10.10b	Salary Continuation Agreements with executive officers, Tani Girton, Chief Financial Officer, dated October 18, 2013 and Elizabeth Reizman, Chief Credit Officer, dated	8-K	001-33572	10.2 10.3	November 4, 2014

Explanation of Responses:

Edgar Filing: Theravance Biopharma, Inc. - Form 4

	July 20, 2014				
10.10c	Salary Continuation Agreements for executive officer Timothy Myers, Executive Vice President and Commercial Banking Manager, dated May 28, 2015	8-K	001-33572	10.4	June 2, 2015
10.11	2007 Form of Change in Control Agreement	8-K	001-33572	10.1	October 31, 2007
10.12	Information Technology Services Agreement with Fidelity Information Services, LLC, dated July 11, 2012	8-K	001-33572	10.1	July 17, 2012

Edgar Filing: Theravance Biopharma, Inc. - Form 4

11.01	Earnings Per Share Computation - included in Note 1 to the Consolidated Financial Statements		Filed
14.02	Code of Ethical Conduct, dated October 17, 2014	10-K001-33572	14.02 March 12, 2015
31.01	Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002		Filed
31.02	Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002		Filed
32.01	Certification pursuant to 18 U.S.C. §1350 as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002		Filed
101.01*	XBRL Interactive Data File		Furnished

*As provided in Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Bank of Marin Bancorp
(registrant)

November 7, 2016 /s/ Russell A. Colombo
Date Russell A. Colombo
President &
Chief Executive Officer
(Principal Executive Officer)

November 7, 2016 /s/ Tani Girton
Date Tani Girton
Executive Vice President &
Chief Financial Officer
(Principal Financial Officer)

November 7, 2016 /s/ Cecilia Situ
Date Cecilia Situ
First Vice President &
Manager of Finance & Treasury
(Principal Accounting Officer)

Page-48